SkyePharma_NNP annual_JJ report_NN 2002_CD 1_CD Accounting_NN policies_NNS until_IN earned_VBN ,_, when_WRB they_PRP are_VBP recognized_VBN as_IN income_NN ._.
Manufacturing_NNP and_CC distribution_NN revenues_NNS principally_RB comprise_VBP contract_NN Accounting_NN convention_NN and_CC presentation_NN manufacturing_NN fees_NNS invoiced_VBD to_TO third_JJ parties_NNS and_CC income_NN from_IN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ product_NN sales_NNS ._.
cost_NN convention_NN and_CC in_IN accordance_NN with_IN applicable_JJ UK_NNP accounting_NN standards_NNS ._.
The_DT principal_JJ accounting_NN policies_NNS ,_, which_WDT have_VBP been_VBN Research_NNP and_CC development_NN costs_NNS applied_VBD consistently_RB ,_, except_IN for_IN the_DT implementation_NN of_IN FRS19_NNP :_: Research_NNP costs_NNS are_VBP charged_VBN as_IN an_DT expense_NN in_IN the_DT period_NN in_IN which_WDT Deferred_NNP Tax_NNP ,_, are_VBP set_VBN out_RP below_IN ._.
The_DT results_NNS for_IN the_DT year_NN all_DT relate_VBP they_PRP are_VBP incurred_VBN ._.
Development_NNP costs_NNS are_VBP also_RB recognized_VBN as_IN an_DT to_TO continuing_VBG operations_NNS ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN expense_NN in_IN the_DT period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ,_, unless_IN all_DT of_IN the_DT prepared_JJ on_IN a_DT going_VBG concern_NN basis_NN ._.
criteria_NNS are_VBP met_VBN for_IN asset_NN recognition_NN ._.
The_DT major_JJ asset_NN recognition_NN criteria_NNS include_VBP :_: the_DT ability_NN to_TO define_VB clearly_RB the_DT product_NN or_CC process_NN ,_, New_NNP accounting_NN policies_NNS and_CC requirements_NNS demonstration_NN of_IN its_PRP$ technical_JJ feasibility_NN and_CC that_IN a_DT commercial_JJ The_DT Group_NNP has_VBZ implemented_VBN FRS_NNP 19_CD :_: Deferred_JJ Tax_NNP ._.
The_DT FRS_NNP market_NN for_IN it_PRP exists_VBZ ._.
Development_NNP costs_VBZ recognized_VBN as_IN an_DT asset_NN do_VBP requires_VBZ deferred_VBN tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN not_RB exceed_VB the_DT probable_JJ net_JJ amount_NN to_TO be_VB recovered_VBN in_IN marketing_VBG basis_NN ,_, rather_RB than_IN the_DT partial_JJ provision_NN basis_NN adopted_VBN in_IN 2001_CD the_DT product_NN or_CC process_NN and_CC they_PRP are_VBP amortised_VBN over_IN the_DT estimated_VBN and_CC earlier_JJR years_NNS ._.
The_DT adoption_NN of_IN FRS_NNP 19_CD has_VBZ had_VBN no_DT material_JJ economic_JJ life_NN ._.
impact_NN on_IN the_DT financial_JJ statements_NNS ._.
Once_RB the_DT Group_NNP has_VBZ achieved_VBN sustained_VBN profitability_NN ,_, the_DT Directors_NNS will_MD consider_VB the_DT Foreign_JJ currency_NN transactions_NNS appropriateness_NN of_IN recognizing_VBG a_DT deferred_JJ tax_NN asset_NN in_IN respect_NN Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP recorded_VBN of_IN losses_NNS carried_VBD forward_RB ._.
in_IN local_JJ currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN transaction_NN ._.
Assets_NNS and_CC liabilities_NNS expressed_VBN in_IN foreign_JJ currencies_NNS Consolidation_NN are_VBP translated_VBN into_IN sterling_NN at_IN the_DT exchange_NN rates_NNS ruling_VBG at_IN the_DT The_DT consolidated_JJ financial_JJ information_NN includes_VBZ the_DT financial_JJ balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS which_WDT relate_VBP to_TO the_DT statements_NNS for_IN the_DT Company_NN ,_, its_PRP$ subsidiary_NN undertakings_NNS and_CC retranslation_NN of_IN net_JJ assets_NNS of_IN overseas_JJ companies_NNS are_VBP taken_VBN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS and_CC results_NNS of_IN associated_VBN directly_RB to_TO reserves_NNS ._.
All_DT other_JJ foreign_JJ exchange_NN differences_NNS are_VBP undertakings_NNS ._.
Intra-group_JJ sales_NNS and_CC profits_NNS are_VBP eliminated_VBN fully_RB taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN in_IN which_WDT they_PRP on_IN consolidation_NN ._.
The_DT results_NNS of_IN subsidiaries_NNS sold_VBN or_CC acquired_VBN are_VBP arise_VB ._.
The_DT Group_NNP uses_VBZ the_DT average_JJ exchange_NN rates_NNS prevailing_VBG included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_VBP up_RP to_TO the_DT date_NN during_IN the_DT year_NN to_TO translate_VB the_DT results_NNS of_IN overseas_JJ subsidiaries_NNS of_IN their_PRP$ sale_NN or_CC from_IN their_PRP$ date_NN of_IN acquisition_NN respectively_RB ._.
The_DT into_IN sterling_NN and_CC year-end_NN rates_NNS to_TO translate_VB the_DT net_JJ assets_NNS of_IN share_NN of_IN results_NNS of_IN associated_VBN undertakings_NNS sold_VBD or_CC acquired_VBD are_VBP those_DT undertakings_NNS ._.
included_VBN in_IN the_DT profit_NN and_CC loss_NN account_VBP up_RP to_TO the_DT date_NN of_IN their_PRP$ sale_NN or_CC from_IN the_DT date_NN of_IN their_PRP$ acquisition_NN respectively_RB ._.
Pension_NN costs_NNS The_DT costs_NNS of_IN the_DT Groups_NNS defined_VBN contribution_NN pension_NN Where_WRB the_DT Group_NNP has_VBZ contractual_JJ agreements_NNS with_IN other_JJ arrangements_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT participants_NNS to_TO engage_VB in_IN joint_JJ activities_NNS that_WDT do_VBP not_RB create_VB year_NN to_TO which_WDT they_PRP relate_VBP ._.
The_DT costs_NNS of_IN the_DT Groups_NNS defined_VBN benefits_NNS an_DT entity_NN carrying_VBG on_IN a_DT trade_NN or_CC business_NN of_IN its_PRP$ own_JJ ,_, they_PRP are_VBP scheme_NN are_VBP charged_VBN on_IN a_DT systematic_JJ basis_NN allowing_VBG for_IN the_DT accounted_VBN for_IN as_IN a_DT joint_JJ arrangement_NN ._.
The_DT Group_NNP includes_VBZ its_PRP$ expected_VBN pension_NN cost_NN over_IN the_DT service_NN lives_NNS of_IN employees_NNS ,_, based_VBN share_NN of_IN the_DT assets_NNS ,_, liabilities_NNS and_CC cash_NN flows_NNS in_IN such_JJ joint_JJ on_IN actuarial_JJ advice_NN ._.
arrangements_NNS measured_VBN in_IN accordance_NN with_IN the_DT terms_NNS of_IN each_DT arrangement_NN ,_, which_WDT is_VBZ usually_RB pro-rata_JJ to_TO the_DT Groups_NNS interest_NN Employee_NNP Share_NNP Plans_NNP in_IN the_DT joint_JJ arrangement_NN ._.
Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
In_IN respect_NN of_IN award_NN Revenue_NN recognition_NN schemes_NNS the_DT Group_NNP provides_VBZ finance_NN to_TO an_DT employee_NN share_NN Turnover_NN comprises_VBZ contract_NN development_NN and_CC licensing_NN ,_, ownership_NN trust_NN to_TO purchase_VB company_NN shares_NNS on_IN the_DT open_JJ market_NN royalty_NN and_CC manufacturing_NN and_CC distribution_NN income_NN ._.
Contract_NN to_TO meet_VB the_DT Groups_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB employees_NNS development_NN and_CC licensing_NN income_NN represents_VBZ amounts_NNS invoiced_VBD exercise_NN their_PRP$ award_NN ._.
The_DT difference_NN between_IN the_DT purchase_NN price_NN to_TO customers_NNS for_IN services_NNS rendered_VBN under_IN development_NN and_CC of_IN the_DT shares_NNS and_CC the_DT exercise_NN price_NN of_IN the_DT award_NN is_VBZ charged_VBN ,_, or_CC licensing_NN agreements_NNS including_VBG milestone_NN payments_NNS and_CC credited_VBN ,_, to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT periods_NNS of_IN service_NN technology_NN access_NN fees_NNS ._.
Contract_NN revenue_NN is_VBZ recognized_VBN when_WRB in_IN respect_NN of_IN which_WDT the_DT award_NN was_VBD granted_VBN ._.
earned_VBN and_CC non-refundable_JJ and_CC when_WRB there_EX are_VBP no_DT future_JJ obligations_NNS pursuant_JJ to_TO the_DT revenue_NN ,_, in_IN accordance_NN with_IN the_DT The_DT costs_NNS of_IN running_VBG the_DT employee_NN share_NN ownership_NN trust_NN are_VBP contract_NN terms_NNS ._.
Refundable_JJ contract_NN revenue_NN is_VBZ treated_VBN as_IN charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP accrue_VBP ._.
deferred_VBN until_IN such_JJ time_NN as_IN it_PRP is_VBZ no_RB longer_RBR refundable_JJ ._.
Royalty_NN income_NN represents_VBZ income_NN earned_VBD as_IN a_DT percentage_NN of_IN product_NN Shares_NNS held_VBN by_IN the_DT employee_NN share_NN ownership_NN trust_NN are_VBP accounted_VBN sales_NNS ._.
Advance_NNP royalties_NNS received_VBD are_VBP treated_VBN as_IN deferred_JJ income_NN for_IN as_IN fixed_JJ asset_NN investments_NNS at_IN cost_NN less_JJR accrual_NN for_IN costs_NNS charged_VBN ._.
notes_NNS to_TO the_DT 57_CD financial_JJ statements_NNS 1_CD Accounting_NN policies_NNS continued_VBD Current_JJ asset_NN investments_NNS Investments_NNP held_VBD other_JJ than_IN for_IN continuing_VBG use_NN in_IN the_DT business_NN are_VBP Intangible_JJ fixed_VBN assets_NNS classified_VBN as_IN current_JJ asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN Intangible_JJ fixed_JJ assets_NNS comprise_VBP goodwill_NN ,_, intellectual_JJ property_NN sheet_NN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Goodwill_NNP ,_, being_VBG the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT purchase_NN consideration_NN and_CC the_DT Liquid_NN resources_NNS Groups_NNS share_NN of_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS acquired_VBN ,_, is_VBZ Liquid_NN resources_NNS comprise_VBP short-term_JJ bank_NN and_CC commercial_JJ capitalized_JJ and_CC amortised_JJ over_IN a_DT period_NN of_IN 20_CD years_NNS or_CC less_JJR in_IN line_NN deposits_NNS with_IN a_DT maturity_NN of_IN less_JJR than_IN one_CD year_NN ._.
with_IN the_DT Directors_NNS view_NN of_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
Prior_RB to_TO the_DT introduction_NN of_IN FRS_NNP 10_CD ,_, the_DT policy_NN adopted_VBN was_VBD to_TO write_VB off_RP goodwill_NN Leased_VBN and_CC hired_VBN assets_NNS to_TO reserves_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 10_CD goodwill_NN written_VBN off_RP to_TO reserves_NNS Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB all_DT in_IN previous_JJ years_NNS has_VBZ not_RB been_VBN reinstated_VBN on_IN the_DT balance_NN sheet_NN and_CC of_IN the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN as_IN adjustments_NNS to_TO such_JJ goodwill_NN have_VBP been_VBN taken_VBN directly_RB to_TO reserves_NNS ._.
finance_NN leases_NNS ,_, as_IN if_IN the_DT asset_NN had_VBD been_VBN purchased_VBN outright_RB ._.
The_DT Goodwill_NNP previously_RB written_VBN off_RP to_TO reserves_NNS is_VBZ charged_VBN to_TO the_DT profit_NN assets_NNS are_VBP included_VBN in_IN tangible_JJ fixed_JJ assets_NNS and_CC the_DT capital_NN element_NN and_CC loss_NN account_NN in_IN the_DT event_NN of_IN disposal_NN of_IN the_DT related_JJ business_NN ._.
of_IN amounts_NNS owed_VBN to_TO the_DT finance_NN company_NN at_IN the_DT balance_NN sheet_NN date_NN is_VBZ included_VBN in_IN creditors_NNS as_IN amounts_NNS falling_VBG due_JJ either_CC within_IN or_CC after_IN Intellectual_NNP property_NN comprises_VBZ acquired_VBN patents_NNS ,_, trade_NN marks_NNS ,_, more_JJR than_IN one_CD year_NN ._.
Repayments_NNS are_VBP treated_VBN as_IN consisting_VBG of_IN both_DT know-how_NN and_CC other_JJ similarly_RB identified_VBN rights_NNS ._.
These_DT are_VBP recorded_JJ capital_NN and_CC interest_NN with_IN the_DT interest_NN element_NN being_VBG charged_VBN to_TO the_DT at_IN their_PRP$ fair_JJ value_NN at_IN acquisition_NN date_NN and_CC are_VBP amortised_VBN in_IN equal_JJ profit_NN and_CC loss_NN account_NN in_IN proportion_NN to_TO the_DT outstanding_JJ obligations_NNS ._.
instalments_NNS over_IN their_PRP$ estimated_VBN useful_JJ economic_JJ lives_NNS ,_, from_IN the_DT Payments_NNS under_IN operating_VBG leases_NNS and_CC short-term_JJ hire_NN contracts_NNS date_NN when_WRB the_DT transfer_NN of_IN technology_NN is_VBZ complete_JJ ._.
The_DT period_NN over_IN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP fall_VBP due_JJ ._.
which_WDT the_DT Group_NNP expects_VBZ to_TO derive_VB economic_JJ benefits_NNS does_VBZ not_RB exceed_VB 20_CD years_NNS ._.
Costs_NNS associated_VBN with_IN internally_RB developed_VBN Convertible_JJ debt_NN intellectual_JJ property_NN are_VBP generally_RB treated_VBN as_IN research_NN and_CC On_IN issue_NN ,_, convertible_JJ debt_NN is_VBZ stated_VBN at_IN the_DT amount_NN of_IN net_JJ proceeds_NNS development_NN costs_NNS ._.
Development_NNP costs_NNS are_VBP recognized_VBN under_IN after_IN deducting_VBG issue_NN costs_NNS ._.
On_IN conversion_NN the_DT amount_NN recognized_VBD the_DT criteria_NNS stated_VBN above_IN ._.
in_IN shareholders_NNS funds_NNS in_IN respect_NN of_IN the_DT shares_NNS issued_VBN is_VBZ equal_JJ to_TO the_DT carrying_VBG value_NN at_IN the_DT date_NN of_IN conversion_NN ._.
Interest_NN payable_JJ on_IN Tangible_JJ fixed_JJ assets_NNS convertible_JJ debt_NN is_VBZ calculated_VBN to_TO unwind_VB the_DT issue_NN costs_NNS and_CC any_DT Tangible_JJ fixed_JJ assets_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN less_JJR discount_NN on_IN issue_NN at_IN a_DT constant_JJ rate_NN over_IN the_DT term_NN of_IN the_DT debt_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN tangible_JJ fixed_JJ assets_NNS at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN ,_, less_JJR estimated_VBN Deferred_JJ consideration_NN residual_JJ value_NN ,_, of_IN each_DT asset_NN over_IN its_PRP$ expected_VBN useful_JJ life_NN ._.
The_DT rates_NNS Provisions_NNS for_IN deferred_JJ consideration_NN comprise_VBP the_DT fair_JJ value_NN of_IN and_CC bases_NNS are_VBP as_IN follows_VBZ :_: contingent_JJ consideration_NN arising_VBG from_IN acquisitions_NNS ._.
The_DT eventual_JJ outcome_NN is_VBZ subject_JJ to_TO the_DT Groups_NNS future_JJ performance_NN and_CC certain_JJ Freehold_NNP land_NN not_RB depreciated_VBD contractual_JJ terms_NNS ._.
Provisions_NNS are_VBP reviewed_VBN annually_RB by_IN the_DT Freehold_NNP buildings_NNS 2_CD %_NN 5_CD %_NN straight_JJ line_NN Directors_NNS ,_, and_CC changes_NNS to_TO the_DT estimated_VBN fair_JJ value_NN of_IN the_DT contingent_JJ Short_JJ leasehold_NN property_NN period_NN of_IN lease_NN consideration_NN are_VBP recorded_VBN as_IN an_DT adjustment_NN to_TO goodwill_NN or_CC the_DT Plant_NN ,_, equipment_NN and_CC fixtures_NNS 10_CD %_NN 33_CD %_NN straight_JJ line_NN underlying_VBG asset_NN value_NN ._.
Where_WRB the_DT effect_NN of_IN the_DT time_NN value_NN of_IN money_NN Motor_NNP vehicles_NNS 20_CD %_NN straight_JJ line_NN is_VBZ material_NN ,_, provisions_NNS are_VBP reflected_VBN at_IN their_PRP$ present_JJ value_NN ,_, and_CC the_DT Finance_NNP leases_VBZ period_NN of_IN lease_NN interest_NN element_NN arising_VBG on_IN discounting_VBG the_DT liability_NN is_VBZ recorded_VBN as_IN interest_NN payable_JJ in_IN the_DT profit_NN and_CC loss_NN account_NN as_IN it_PRP unwinds_VBZ ._.
Fixed_JJ asset_NN investments_NNS Investments_NNP that_WDT are_VBP held_VBN for_IN continuing_VBG use_NN in_IN the_DT business_NN are_VBP Deferred_VBN taxation_NN classified_VBN as_IN fixed_JJ asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN Deferred_VBN taxation_NN is_VBZ provided_VBN on_IN timing_NN differences_NNS which_WDT at_IN the_DT sheet_NN at_IN cost_NN or_CC Directors_NNS valuation_NN ,_, less_JJR provision_NN for_IN permanent_JJ balance_NN sheet_NN date_NN result_NN in_IN an_DT obligation_NN to_TO pay_VB more_JJR tax_NN or_CC a_DT right_JJ diminution_NN in_IN value_NN ._.
to_TO pay_VB less_JJR tax_NN at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN rates_NNS and_CC law_NN ._.
Deferred_JJ tax_NN assets_NNS Impairment_NN of_IN fixed_JJ assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN The_DT carrying_VBG values_NNS of_IN fixed_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS may_MD be_VB impaired_VBN ._.
year_NN impairment_NN reviews_NNS are_VBP conducted_VBN for_IN acquired_VBN goodwill_NN and_CC intangible_JJ assets_NNS ._.
Impairment_NN is_VBZ determined_VBN by_IN reference_NN to_TO the_DT Financial_NNP instruments_NNS higher_JJR of_IN net_JJ realisable_JJ value_NN and_CC value_NN in_IN use_NN ,_, which_WDT is_VBZ measured_VBN The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO hedge_VB its_PRP$ by_IN reference_NN to_TO discounted_JJ future_JJ cash_NN flows_NNS ._.
Any_DT provision_NN for_IN exposure_NN to_TO fluctuations_NNS in_IN interest_NN and_CC foreign_JJ exchange_NN rates_NNS ._.
impairment_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN Specifically_RB ,_, the_DT Group_NNP uses_VBZ interest_NN rate_NN swaps_NNS ,_, forward_RB currency_NN concerned_VBN ._.
Receipts_NNPS and_CC payments_NNS on_IN interest_NN rate_NN swaps_NNS are_VBP recognized_VBN on_IN an_DT accruals_NNS basis_NN ,_, over_IN the_DT life_NN of_IN the_DT Stock_NN and_CC work-in-progress_NN swap_NN ,_, as_IN an_DT adjustment_NN to_TO interest_NN payable_JJ ._.
Gains_NNS and_CC losses_NNS on_IN Stock_NNP and_CC work-in-progress_NN are_VBP valued_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC forward_JJ currency_NN contracts_NNS and_CC currency_NN options_NNS are_VBP not_RB recognized_VBN net_JJ realisable_JJ value_NN and_CC calculated_VBN using_VBG the_DT first-in_NN ,_, first-out_JJ basis_NN ._.
until_IN the_DT period_NN that_IN the_DT foreign_JJ currency_NN exposure_NN is_VBZ recognized_VBN ._.
Option_NN premia_NN are_VBP deferred_VBN in_IN the_DT balance_NN sheet_NN and_CC recognized_VBN upon_IN the_DT maturity_NN of_IN the_DT option_NN agreement_NN ._.
notes_NNS to_TO the_DT financial_JJ 58_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 2_CD Segmental_JJ analysis_NN The_DT Groups_NNS operations_NNS relate_VBP wholly_RB to_TO one_CD class_NN of_IN business_NN ,_, pharmaceuticals_NNS ._.
Further_JJ analysis_NN of_IN turnover_NN ,_, operating_VBG profit_NN loss_NN and_CC net_JJ assets_NNS by_IN geographical_JJ area_NN is_VBZ set_VBN out_RP below_IN ,_, together_RB with_IN an_DT analysis_NN of_IN cost_NN of_IN sales_NNS ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD a_DT Turnover_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN Milestone_NN payments_NNS 47,736_CD 28,379_CD Research_NNP and_CC development_NN costs_NNS recharged_VBD 7,705_CD 9,857_CD 55,441_CD 38,236_CD Royalties_NNS receivable_JJ 6,751_CD 1,468_CD Manufacturing_NNP and_CC distribution_NN 7,381_CD 6,422_CD 69,573_CD 46,126_CD By_IN location_NN of_IN customer_NN :_: North_NNP America_NNP 34,047_CD 5,482_CD UK_NNP 21,000_CD 21,411_CD Europe_NNP 10,333_CD 16,511_CD Rest_VBP of_IN the_DT world_NN 4,193_CD 2,722_CD 69,573_CD 46,126_CD By_IN location_NN of_IN operation_NN :_: Europe_NNP 34,449_CD 30,268_CD North_NNP America_NNP 35,124_CD 15,858_CD 69,573_CD 46,126_CD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD b_NN Cost_NN of_IN sales_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN 12,649_CD 7,917_CD Royalties_NNS payable_JJ 1,374_CD 572_CD Manufacturing_NNP and_CC distribution_NN 10,807_CD 10,331_CD 24,830_CD 18,820_CD 59_CD 2_CD Segmental_JJ analysis_NN continued_VBD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD c_NN Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 1,333_CD 9,377_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 7,695_CD 6,840_CD Europe_NNP 7,652_CD 6,985_CD North_NNP America_NNP 4,759_CD 5,244_CD Operating_NN profit_NN loss_NN 4,716_CD 5,099_CD Associated_NNP undertaking_NN 578_CD Net_JJ interest_NN payable_JJ 3,383_CD 3,700_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 1,333_CD 9,377_CD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD d_SYM Net_JJ assets_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 124,270_CD 95,145_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 151,673_CD 136,410_CD Europe_NNP 69,489_CD 74,268_CD North_NNP America_NNP 42,086_CD 33,003_CD 124,270_CD 95,145_CD 3_CD Other_JJ operating_NN income_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP have_VBP provided_VBN a_DT total_NN of_IN $_$ 30_CD million_CD between_IN 2000_CD and_CC 2002_CD ,_, to_TO fund_VB the_DT clinical_JJ development_NN and_CC regulatory_JJ submission_NN of_IN DepoMorphine_NNP ,_, in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN future_JJ royalty_NN and_CC revenue_NN streams_NNS from_IN DepoMorphine_NNP ,_, Xatral_NNP OD_NNP ,_, Solaraze_NNP and_CC DepoCyt_NNP ._.
Income_NN of_IN 9.7_CD million_CD 2001_CD :_: 6.3_CD million_CD was_VBD recognized_VBN as_IN other_JJ operating_NN income_NN under_IN this_DT agreement_NN on_IN a_DT cost_NN to_TO complete_VB basis_NN ._.
No_DT royalty_NN payments_NNS have_VBP been_VBN made_VBN to_TO Paul_NNP Capital_NNP under_IN this_DT agreement_NN during_IN the_DT year_NN ._.
In_IN March_NNP 2002_CD the_DT Group_NNP announced_VBD another_DT transaction_NN under_IN which_WDT Paul_NNP Capital_NNP will_MD pay_VB SkyePharma_NNP a_DT further_JJ $_$ 30_CD million_CD during_IN 2002_CD and_CC 2003_CD ,_, principally_RB to_TO fund_VB the_DT clinical_JJ development_NN of_IN Propofol_NNP IDD-D_NNP and_CC HFA-formoterol_NNP ._.
In_IN return_NN ,_, SkyePharma_NNP has_VBZ agreed_VBN to_TO sell_VB a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS from_IN these_DT ,_, and_CC seven_CD other_JJ products_NNS from_IN the_DT drug_NN pipeline_NN to_TO Paul_NNP Capital_NNP ._.
Income_NN of_IN 4.5_CD million_CD 2001_CD :_: nil_NN was_VBD recognized_VBN as_IN other_JJ operating_NN income_NN under_IN this_DT agreement_NN on_IN a_DT cost_NN to_TO complete_VB basis_NN ._.
Royalty_NN payments_NNS of_IN 0.7_CD million_CD $_$ 1_CD million_CD have_VBP been_VBN made_VBN to_TO Paul_NNP Capital_NNP under_IN this_DT agreement_NN during_IN the_DT year_NN ,_, and_CC are_VBP included_VBN within_IN royalties_NNS payable_JJ ._.
notes_NNS to_TO the_DT financial_JJ 60_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 4_CD Operating_NN profit_NN loss_NN Operating_NN profit_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Auditors_NNS remuneration_JJ audit_NN of_IN SkyePharma_NNP PLC_NNP 194_CD 93_CD audit_NN of_IN subsidiary_NN undertakings_NNS overseas_RB 160_CD 101_CD Fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN auditors_NNS UK_NNP firm_NN 1,045_CD 499_CD auditors_NNS overseas_JJ firms_NNS 214_CD 240_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS owned_VBN assets_NNS 5,616_CD 4,343_CD assets_NNS held_VBN under_IN finance_NN leases_NNS 485_CD 435_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS amortisation_NN of_IN goodwill_NN 3,799_CD 2,844_CD amortisation_NN of_IN intellectual_JJ property_NN 2,483_CD 1,282_CD Research_NNP and_CC development_NN expenses_NNS current_JJ year_NN expenditure_NN 29,285_CD 17,918_CD amortisation_NN of_IN deferred_VBN expenditure_NN 224_CD 201_CD Operating_NN lease_NN rentals_NNS hire_VB of_IN plant_NN and_CC machinery_NN 434_CD 266_CD other_JJ 3,336_CD 3,659_CD It_PRP is_VBZ the_DT Groups_NNS policy_NN to_TO employ_VB the_DT auditors_NNS on_IN assignments_NNS additional_JJ to_TO their_PRP$ statutory_JJ audit_NN duties_NNS where_WRB their_PRP$ expertise_NN and_CC experience_NN with_IN the_DT Group_NNP are_VBP important_JJ ,_, principally_RB tax_NN advice_NN and_CC due_JJ diligence_NN reporting_VBG on_IN acquisitions_NNS ,_, or_CC where_WRB they_PRP are_VBP awarded_VBN assignments_NNS on_IN a_DT competitive_JJ basis_NN ._.
During_IN the_DT year_NN the_DT auditors_NNS earned_VBD the_DT following_VBG non-audit_JJ fees_NNS from_IN the_DT Group_NNP :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Due_JJ diligence_NN and_CC other_JJ audit-related_JJ work_NN 311_CD 215_CD Tax_NNP advice_NN 681_CD 297_CD Accounting_NN advice_NN and_CC regulatory_JJ returns_NNS 267_CD 227_CD Total_JJ non-audit_JJ fees_NNS 1,259_CD 739_CD 5_CD Employees_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Employment_NNP costs_NNS :_: Wages_NNS and_CC salaries_NNS 20,614_CD 15,502_CD Social_NNP security_NN costs_NNS 3,091_CD 2,451_CD Pension_NN costs_NNS 1,525_CD 822_CD 25,230_CD 18,775_CD The_DT average_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Number_NNP Number_NNP Pharmaceuticals_NNP 492_CD 411_CD 61_CD 6_CD Interest_NN receivable_NN Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Interest_NN 1,081_CD 1,215_CD Share_NN of_IN interest_NN receivable_NN of_IN associate_JJ 36_CD 1,081_CD 1,251_CD 7_CD Interest_NN payable_JJ Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Interest_NN payable_JJ on_IN bank_NN loans_NNS ,_, overdrafts_NNS and_CC other_JJ loans_NNS :_: Repayable_JJ within_IN five_CD years_NNS ,_, not_RB by_IN instalments_NNS 88_CD 91_CD Repayable_JJ within_IN five_CD years_NNS ,_, by_IN instalments_NNS 112_CD 470_CD Repayable_JJ wholly_RB or_CC partly_RB in_IN more_JJR than_IN five_CD years_NNS 373_CD 360_CD Finance_NNP leases_VBZ 130_CD 170_CD Interest_NN on_IN convertible_JJ bonds_NNS 3,761_CD 3,860_CD 4,464_CD 4,951_CD 8_CD Taxation_NNP Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, is_VBZ analyzed_VBN over_IN its_PRP$ component_NN parts_NNS as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD UK_NNP 146_CD 1,269_CD Overseas_JJ 1,187_CD 10,646_CD 1,333_CD 9,377_CD Current_JJ taxation_NN charge_NN based_VBN on_IN profits_NNS for_IN the_DT year_NN :_: Overseas_NNP taxation_NN 224_CD 75_CD 224_CD 75_CD Overseas_JJ taxation_NN relates_VBZ principally_RB to_TO withholding_VBG tax_NN paid_VBN on_IN remittance_NN of_IN milestones_NNS to_TO the_DT US_NNP and_CC royalties_NNS to_TO Switzerland_NNP which_WDT are_VBP not_RB recoverable_JJ ._.
There_EX was_VBD no_DT deferred_JJ tax_NN component_NN in_IN the_DT tax_NN charge_NN for_IN the_DT years_NNS presented_VBN ._.
The_DT Group_NNP has_VBZ estimated_VBN total_JJ tax_NN losses_NNS available_JJ to_TO be_VB set_VBN off_RP against_IN future_JJ taxable_JJ profits_NNS of_IN 178.9_CD million_CD 31_CD December_NNP 2001_CD :_: 163.9_CD million_CD ._.
These_DT losses_NNS arise_VBP primarily_RB in_IN the_DT UK_NNP ,_, Switzerland_NNP and_CC US_NNP ._.
Of_IN the_DT 178.9_CD million_CD of_IN losses_NNS carried_VBD forward_RB ,_, 0.3_CD million_CD expire_VBP in_IN 2003_CD ,_, 52.0_CD million_CD expire_VBP between_IN 2004_CD and_CC 2006_CD ,_, 120.8_CD million_CD expire_VBP from_IN 2007_CD onwards_NNS and_CC 5.8_CD million_CD of_IN losses_NNS may_MD be_VB carried_VBN forward_RB indefinitely_RB ._.
The_DT above_IN charges_NNS reconcile_VBP with_IN the_DT applicable_JJ UK_NNP statutory_JJ corporation_NN tax_NN rate_NN as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD %_NN %_NN Statutory_NNP UK_NNP Corporation_NNP tax_NN rate_NN 30.0_CD 30.0_CD Tax_NNP rate_NN differences_NNS 18.2_CD 19.0_CD Permanent_JJ differences_NNS 19.1_CD 16.9_CD Tax_NNP losses_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 23.6_CD 35.0_CD Other_JJ items_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 26.9_CD 31.7_CD Effective_JJ tax_NN rate_NN 16.8_CD 0.8_CD notes_NNS to_TO the_DT financial_JJ 62_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 9_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Basic_JJ and_CC diluted_JJ attributable_JJ profit_NN loss_NN 000_CD 1,109_CD 9,452_CD Basic_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 000_CD 577,018_CD 526,250_CD Dilutive_JJ potential_JJ Ordinary_NNP Shares_NNP 000_CD 20,077_CD Diluted_VBN weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 000_CD 597,095_CD 526,250_CD For_IN diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NNP ,_, the_DT weighted_JJ average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT dilutive_JJ potential_JJ Ordinary_NNP Shares_NNP ._.
In_IN 2001_CD there_EX was_VBD no_DT difference_NN between_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP since_IN all_DT potential_JJ Ordinary_NNP Shares_NNP were_VBD anti-dilutive_JJ ._.
Shares_NNS held_VBN by_IN the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP are_VBP excluded_VBN from_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS ._.
10_CD Intangible_JJ fixed_JJ assets_NNS Intellectual_NNP Development_NNP Goodwill_NNP property_NN costs_NNS Total_JJ Group_NNP 000 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2002_CD 75,762_CD 30,496_CD 1,716_CD 107,974_CD Exchange_NNP adjustments_NNS 663_CD 62_CD 725_CD Additions_NNS 285_CD 3,401_CD 3,686_CD Acquisitions_NNS 3,970_CD 3,970_CD At_IN 31_CD December_NNP 2002_CD 80,017_CD 34,560_CD 1,778_CD 116,355_CD Amortisation_NNP At_IN 1_CD January_NNP 2002_CD 6,154_CD 2,974_CD 618_CD 9,746_CD Exchange_NNP adjustments_NNS 82_CD 6_CD 88_CD Charge_NNP for_IN the_DT year_NN 3,799_CD 2,483_CD 224_CD 6,506_CD At_IN 31_CD December_NNP 2002_CD 9,953_CD 5,539_CD 848_CD 16,340_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 69,608_CD 27,522_CD 1,098_CD 98,228_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 70,064_CD 29,021_CD 930_CD 100,015_CD In_IN May_NNP 2002_CD ,_, SkyePharma_NNP acquired_VBD the_DT entire_JJ drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP for_IN 3.6_CD million_CD in_IN cash_NN and_CC the_DT assumption_NN of_IN 0.4_CD million_CD of_IN net_JJ liabilities_NNS ._.
The_DT acquired_VBN rights_NNS included_VBD Bioglans_NNP Biosphere_NNP injectable_JJ technology_NN and_CC those_DT rights_NNS to_TO DermaStick_NNP ,_, Crystalip_NNP and_CC ES-Gel_NNP topical_JJ technologies_NNS that_WDT had_VBD remained_VBN with_IN Bioglan_NNP after_IN the_DT January_NNP 2001_CD development_NN and_CC commercialisation_NN licensing_NN agreement_NN with_IN Bioglan_NNP ._.
Tangible_JJ fixed_JJ assets_NNS include_VBP net_JJ book_NN value_NN of_IN 2,384,000_CD 31_CD December_NNP 2001_CD :_: 2,314,000_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS ._.
Land_NNP and_CC Office_NNP and_CC other_JJ Motor_NNP buildings_NNS equipment_NN vehicles_NNS Total_JJ Company_NN 000 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2002 107 477_CD 75_CD 659_CD Additions_NNPS 46_CD 46_CD Disposals_NNS 191_CD 191_CD At_IN 31_CD December_NNP 2002 107 332_CD 75_CD 514_CD Depreciation_NN At_IN 1_CD January_NNP 2002_CD 65_CD 377_CD 74_CD 516_CD Charge_NNP for_IN the_DT year_NN 11_CD 41_CD 1_CD 53_CD Disposals_NNS 189_CD 189_CD At_IN 31_CD December_NNP 2002_CD 76_CD 229_CD 75_CD 380_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 42_CD 100_CD 1_CD 143_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002 31 103 134_CD notes_NNS to_TO the_DT financial_JJ 64_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 12_CD Fixed_NNP Asset_NNP Investments_NNP a_DT Group_NNP Unlisted_NNP Own_NNP investments_NNS shares_NNS Total_JJ 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 13,659_CD 552_CD 14,211_CD Additions_NNPS 5,215_CD 1,070_CD 6,285_CD Charge_NNP for_IN the_DT year_NN 594_CD 594_CD At_IN 31_CD December_NNP 2002_CD 18,874_CD 1,028_CD 19,902_CD Astralis_NNP Limited_NNP Astralis_NNP Ltd_NNP is_VBZ an_DT emerging_VBG biotechnology_NN company_NN based_VBN in_IN the_DT US_NNP ,_, and_CC engaged_VBD primarily_RB in_IN the_DT research_NN and_CC development_NN of_IN novel_NN treatments_NNS for_IN immune_JJ system_NN disorders_NNS and_CC skin_NN diseases_NNS ._.
The_DT company_NN is_VBZ currently_RB developing_VBG two_CD products_NNS ._.
Its_PRP$ primary_JJ product_NN ,_, Psoraxine_NNP ,_, is_VBZ an_DT innovative_JJ vaccine_NN under_IN development_NN for_IN the_DT treatment_NN of_IN psoriasis_NN ._.
The_DT companys_NNS second_JJ product_NN is_VBZ for_IN the_DT treatment_NN of_IN leishmaniasis_NN ._.
During_IN the_DT year_NN SkyePharma_NNP acquired_VBD a_DT further_JJ 750,000_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS of_IN Astralis_NNP Limited_NNP for_IN 5.2_CD million_CD $_$ 7.5_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 200,000_CD common_JJ shares_NNS ,_, 20,000_CD warrants_NNS and_CC 1,750,000_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS ,_, representing_VBG approximately_RB 23.0_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN assuming_VBG conversion_NN ._.
The_DT shares_NNS ,_, warrants_NNS and_CC convertible_JJ preferred_JJ shares_NNS are_VBP held_VBN at_IN cost_NN of_IN 12.7_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD Astralis_NNP had_VBD net_JJ assets_NNS of_IN 4.9_CD million_CD and_CC a_DT retained_VBN loss_NN for_IN the_DT year_NN of_IN 12.2_CD million_CD ._.
Transition_NN Therapeutics_NNPS Inc._NNP is_VBZ a_DT biopharmaceutical_JJ company_NN based_VBN in_IN Canada_NNP and_CC engaged_VBN primarily_RB in_IN the_DT business_NN of_IN developing_VBG products_NNS for_IN the_DT treatment_NN of_IN multiple_JJ sclerosis_NN ,_, diabetes_NN and_CC restenosis_NN ._.
As_IN at_IN 31_CD December_NNP 2002_CD ,_, the_DT total_JJ SkyePharma_NNP holding_NN of_IN Transition_NN was_VBD 4,930,814_CD shares_NNS ,_, representing_VBG approximately_RB 8.2_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT shares_NNS are_VBP recorded_VBN at_IN cost_NN of_IN 2.2_CD million_CD ._.
Cade_NNP Struktur_NNP Corp._NNP ._.
As_IN at_IN 31_CD December_NNP 2002_CD ,_, the_DT total_JJ SkyePharma_NNP holding_NN of_IN Cade_NNP Struktur_NNP Corp._NNP a_DT Canadian_JJ company_NN ,_, was_VBD 869,086_CD shares_NNS ,_, representing_VBG approximately_RB 16.8_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
SkyePharma_NNP has_VBZ not_RB attributed_VBN a_DT value_NN to_TO these_DT shares_NNS and_CC they_PRP have_VBP been_VBN recorded_VBN at_IN zero_CD cost_NN ._.
The_DT shares_NNS were_VBD originally_RB acquired_VBN consequent_JJ upon_IN the_DT acquisition_NN of_IN the_DT assets_NNS of_IN Hyal_NNP Pharmaceutical_NNP Corp._NNP ._.
Other_JJ investments_NNS The_DT Group_NNP has_VBZ other_JJ investments_NNS of_IN 4.0_CD million_CD in_IN a_DT collaborative_JJ partner_NN based_VBN in_IN the_DT US_NNP ,_, representing_VBG approximately_RB 14.2_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN assuming_VBG conversion_NN ,_, recorded_VBN at_IN Directors_NNS valuation_NN based_VBN on_IN a_DT number_NN of_IN considerations_NNS including_VBG comparable_JJ transactions_NNS and_CC discounted_JJ future_JJ cash_NN flows_NNS ._.
Own_JJ shares_NNS During_IN 2001_CD the_DT Company_NN established_VBD an_DT employee_NN share_NN ownership_NN trust_NN ,_, the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP ._.
The_DT purpose_NN of_IN the_DT trust_NN is_VBZ to_TO hold_VB shares_NNS in_IN the_DT Company_NN ,_, which_WDT may_MD subsequently_RB be_VB awarded_VBN to_TO Directors_NNS and_CC employees_NNS under_IN the_DT Deferred_NNP Share_NNP Bonus_NNP Plan_NNP and_CC Share_NNP Purchase_NNP Plans_NNP ._.
Further_JJ details_NNS of_IN these_DT plans_NNS are_VBP described_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
During_IN the_DT year_NN ,_, the_DT trust_NN purchased_VBD 2_CD million_CD shares_NNS and_CC 893,415_CD shares_NNS were_VBD allocated_VBN at_IN an_DT average_JJ price_NN of_IN 66_CD pence_NN per_IN share_NN ._.
As_IN at_IN 31_CD December_NNP 2002_CD the_DT trust_NN held_VBD 1,805,681_CD shares_NNS at_IN a_DT carrying_VBG value_NN of_IN 1.0_CD million_CD and_CC a_DT market_NN value_NN of_IN 0.7_CD million_CD ._.
This_DT shortfall_NN is_VBZ not_RB considered_VBN to_TO represent_VB a_DT permanent_JJ diminution_NN in_IN value_NN ._.
b_NN Company_NN Shares_NNS in_IN Loans_NNS to_TO Group_NNP Group_NNP Unlisted_NNP Own_NNP undertakings_NNS undertakings_NNS investments_NNS shares_NNS Total_JJ 000 000 000 000_CD 000_CD At_IN 1_CD January_NNP 2002_CD 203,847_CD 173,311_CD 7,481_CD 552_CD 385,191_CD Additions_NNPS 4,262_CD 8,000_CD 5,215_CD 1,070_CD 18,547_CD Revaluation_NNP of_IN shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN note_NN 23_CD 4,837_CD 4,837_CD Lapse_NN of_IN warrants_NNS 1,096_CD 1,096_CD Charge_NNP for_IN the_DT year_NN 594_CD 594_CD At_IN 31_CD December_NNP 2002_CD 202,176_CD 181,311_CD 12,696_CD 1,028_CD 397,211_CD 65_CD 13_CD Stock_NNP Group_NNP Group_NNP 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 919_CD 896_CD Work_NN in_IN progress_NN 263_CD 1,313_CD Finished_VBN goods_NNS 74_CD 69_CD 1,256_CD 2,278_CD The_DT replacement_NN cost_NN of_IN stock_NN is_VBZ not_RB materially_RB different_JJ from_IN original_JJ cost_NN ._.
14_CD Debtors_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000 000_CD 000_CD Trade_NNP debtors_NNS 26,327_CD 8,662_CD Amounts_NNS owed_VBN by_IN subsidiary_NN undertakings_NNS 24,310_CD 13,273_CD Other_JJ debtors_NNS 2,224_CD 1,829_CD 122_CD 92_CD Prepayments_NNS and_CC accrued_VBN income_NN 6,502_CD 3,515_CD 1,465_CD 673_CD Interest_NN receivable_NN 154_CD 16_CD 154_CD 16_CD 35,207_CD 14,022_CD 26,051_CD 14,054_CD 15_CD Current_JJ Asset_NNP Investments_NNP Current_JJ asset_NN investments_NNS are_VBP represented_VBN by_IN a_DT convertible_JJ loan_NN note_VBP the_DT notes_NNS carrying_VBG a_DT 5_CD %_NN coupon_NN ,_, due_JJ at_IN par_NN with_IN accrued_VBN interest_NN in_IN June_NNP 2007_CD ._.
The_DT notes_NNS were_VBD received_VBN from_IN GeneMedix_NNP plc_NN in_IN June_NNP 2002_CD as_IN an_DT initial_JJ payment_NN under_IN an_DT agreement_NN to_TO jointly_RB develop_VB an_DT extended_JJ release_NN formulation_NN of_IN interferon_NN alpha-2b_JJ using_VBG SkyePharmas_NNP DepoFoam_NNP technology_NN ._.
The_DT notes_NNS are_VBP convertible_JJ at_IN any_DT time_NN ,_, at_IN SkyePharmas_NNP option_NN ,_, into_IN between_IN approximately_RB 8.3_CD million_CD and_CC 11.2_CD million_CD GeneMedix_NNP ordinary_JJ shares_NNS ._.
There_EX are_VBP no_DT restrictions_NNS or_CC a_DT lock-up_JJ period_NN on_IN conversion_NN of_IN the_DT notes_NNS ._.
GeneMedix_NNP can_MD elect_VB to_TO redeem_VB in_IN cash_NN some_DT or_CC all_DT of_IN the_DT notes_NNS on_IN conversion_NN under_IN certain_JJ circumstances_NNS ._.
The_DT notes_NNS have_VBP been_VBN recorded_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN assuming_VBG conversion_NN ._.
16_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000 000_CD 000_CD Bank_NNP overdrafts_NNS 1,618_CD Bank_NNP loans_NNS 1,572_CD 1,521_CD Current_JJ portion_NN of_IN secured_JJ mortgage_NN note_NN 17 270 248_CD Current_JJ portion_NN of_IN Chiron_NNP loan_NN note_NN 3,023_CD Trade_NNP creditors_NNS 3,344_CD 3,716_CD 69_CD 260_CD Amounts_NNS owed_VBN to_TO subsidiary_NN undertakings_NNS 10,229_CD 4,553_CD Corporation_NNP tax_NN 3_CD 3_CD Other_JJ taxation_NN and_CC social_JJ security_NN costs_NNS 893_CD 1,031_CD 83_CD 53_CD Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS 1,085_CD 847_CD Deferred_JJ income_NN 15,069_CD 11,690_CD Accruals_NNPS 12,235_CD 11,491_CD 3,431_CD 3,467_CD 34,471_CD 35,188_CD 13,812_CD 8,333_CD At_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD loans_NNS with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 0.9_CD million_CD CHF_NNP 2_CD million_CD and_CC 0.7_CD million_CD CHF_NNP 1.5_CD million_CD ._.
These_DT loans_NNS are_VBP renewable_JJ annually_RB and_CC bear_VB interest_NN at_IN 6.5_CD %_NN and_CC 6.0_CD %_NN respectively_RB ._.
The_DT loans_NNS are_VBP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP and_CC guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
notes_NNS to_TO the_DT financial_JJ 66_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 17_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000 000_CD 000_CD Secured_JJ mortgage_NN 7,502_CD 7,159_CD Chiron_NNP promissory_JJ note_NN 621_CD Chiron_NNP loan_NN note_NN 802_CD Accrued_VBN rent_NN 3,269_CD 3,385_CD Convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 58,377_CD 57,962_CD 58,377_CD 57,962_CD Deferred_JJ income_NN 2,960_CD Obligations_NNS under_IN finance_NN leases_NNS 235_CD 874_CD 72,964_CD 70,182_CD 58,377_CD 57,962_CD Bank_NNP and_CC other_JJ loans_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 5,158_CD 1,050_CD Between_IN two_CD and_CC three_CD years_NNS 180_CD 4,179_CD Between_IN three_CD and_CC four_CD years_NNS 180_CD 166_CD Between_IN four_CD and_CC five_CD years_NNS 180_CD 166_CD After_IN five_CD years_NNS 2,425_CD 2,400_CD 8,123_CD 7,961_CD Obligations_NNS under_IN finance_NN leases_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 97_CD 843_CD Between_IN two_CD and_CC three_CD years_NNS 55_CD 27_CD Between_IN three_CD and_CC four_CD years_NNS 83_CD 4_CD 235_CD 874_CD At_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD a_DT property_NN mortgage_NN facility_NN with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 7.8_CD million_CD CHF_NNP 17.3_CD million_CD of_IN which_WDT 0.3_CD million_CD CHF_NNP 0.6_CD million_CD is_VBZ shown_VBN within_IN current_JJ liabilities_NNS ._.
The_DT mortgage_NN is_VBZ in_IN two_CD tranches_NNS ,_, both_DT secured_VBN by_IN the_DT assets_NNS of_IN Jago_NNP and_CC guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
The_DT first_JJ tranche_NN of_IN 3.3_CD million_CD CHF_NNP 7.4_CD million_CD bears_NNS interest_NN at_IN 4.25_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 21_CD years_NNS semi-annually_RB ._.
The_DT second_JJ tranche_NN of_IN 4.5_CD million_CD CHF_NNP 9.9_CD million_CD bears_NNS interest_NN at_IN 3.0_CD %_NN and_CC is_VBZ repayable_JJ in_IN 2004_CD ._.
At_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD a_DT promissory_JJ note_NN with_IN Chiron_NNP of_IN 0.6_CD million_CD $_$ 1_CD million_CD which_WDT formed_VBD part_NN of_IN the_DT consideration_NN for_IN the_DT reacquisition_NN of_IN the_DT DepoCyt_NNP marketing_NN ,_, distribution_NN and_CC sales_NNS rights_NNS ._.
The_DT promissory_JJ note_NN is_VBZ repayable_JJ in_IN 2004_CD and_CC bears_VBZ interest_NN at_IN LIBOR_NNP plus_CC 300_CD points_NNS ._.
It_PRP is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
The_DT Chiron_NNP loan_NN note_NN was_VBD settled_VBN during_IN the_DT year_NN ._.
In_IN June_NNP 2000_CD ,_, the_DT Company_NN issued_VBN 59.4_CD million_CD 6_CD %_NN Convertible_JJ Bonds_NNS the_DT Bonds_NNS due_JJ 2005_CD ._.
The_DT Bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 83_CD pence_NN at_IN any_DT time_NN up_RP to_TO 19_CD June_NNP 2005_CD ._.
Unless_IN previously_RB redeemed_VBN or_CC converted_VBN ,_, the_DT Bonds_NNS will_MD be_VB redeemed_VBN by_IN the_DT Company_NN at_IN their_PRP$ principal_JJ amount_NN on_IN 19_CD June_NNP 2005_CD ._.
67_CD 18_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS National_NNP Total_NNP Pension_NNP Insurance_NNP Total_NNP Group_NNP 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 51_CD 17_CD 68_CD Exchange_NNP adjustments_NNS 22_CD 22_CD Charged_VBN in_IN the_DT year_NN 128_CD 128_CD Utilised_VBN 17_CD 17_CD At_IN 31_CD December_NNP 2002 201 201_CD National_NNP Insurance_NNP Company_NNP 000_CD At_IN 1_CD January_NNP 2002_CD 3_CD Utilised_VBN 3_CD At_IN 31_CD December_NNP 2002_CD Pension_NNP provision_NN The_DT pension_NN provision_NN relates_VBZ to_TO the_DT retirement_NN commitments_NNS under_IN a_DT defined_VBN benefit_NN scheme_NN for_IN SkyePharma_NNP Production_NNP SAS_NNP employees_NNS note_VBP 26_CD :_: Pension_NNP Arrangements_NNP ._.
National_NNP Insurance_NNP provision_NN A_DT balance_NN sheet_NN provision_NN of_IN Nil_NNP 31_CD December_NNP 2001_CD :_: 17,000_CD has_VBZ been_VBN recognized_VBN in_IN accordance_NN with_IN UITF25_NNP :_: National_NNP Insurance_NNP contributions_NNS on_IN share_NN option_NN gains_NNS ._.
19_CD Deferred_JJ taxation_NN Group_NNP Full_NNP potential_JJ Company_NN Full_NNP potential_JJ 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000 000_CD 000_CD Accelerated_VBN capital_NN allowances_NNS 4,848_CD 4,030_CD 42_CD 36_CD Other_JJ timing_NN differences_NNS 6,866_CD 10,891_CD 17_CD 14_CD UK_NNP tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 1,288_CD 1,893_CD 1,288_CD 1,893_CD Overseas_JJ tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 29,731_CD 31,480_CD Potential_JJ deferred_JJ tax_NN asset_NN 42,733_CD 48,294_CD 1,347_CD 1,943_CD No_DT deferred_VBN tax_NN asset_NN is_VBZ recognized_VBN ,_, given_VBN the_DT uncertainty_NN of_IN the_DT recoverability_NN of_IN the_DT Groups_NNS tax_NN losses_NNS carried_VBD forward_RB ._.
20_CD Contingent_JJ liabilities_NNS and_CC guarantees_NNS At_IN 31_CD December_NNP 2002_CD the_DT Company_NN had_VBD provided_VBN guarantees_NNS on_IN various_JJ bank_NN borrowings_NNS of_IN its_PRP$ subsidiaries_NNS as_IN set_VBN out_RP in_IN note_NN 16_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN and_CC note_NN 17_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN ._.
In_IN December_NNP 1999_CD SkyePharma_NNP Production_NNP SAS_NNP entered_VBD into_IN a_DT leasing_NN arrangement_NN with_IN Lombard_NNP North_NNP Central_NNP PLC_NNP by_IN which_WDT certain_JJ pharmaceutical_JJ manufacturing_NN and_CC laboratory_NN equipment_NN was_VBD the_DT subject_NN of_IN a_DT four-year_JJ sale_NN and_CC leaseback_NN arrangement_NN ._.
The_DT Company_NN has_VBZ guaranteed_VBN the_DT obligations_NNS of_IN the_DT lessee_NN under_IN this_DT lease_NN to_TO an_DT amount_NN of_IN 3.0_CD million_CD a4_JJ .6_CD million_CD ._.
In_IN common_JJ with_IN most_JJS business_NN enterprises_NNS ,_, Group_NNP companies_NNS are_VBP subject_JJ to_TO a_DT number_NN of_IN claims_NNS from_IN third_JJ parties_NNS ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN but_CC which_WDT are_VBP not_RB considered_VBN to_TO be_VB material_NN in_IN the_DT context_NN of_IN these_DT Financial_NNP Statements_NNP ._.
Provision_NNP has_VBZ been_VBN made_VBN in_IN these_DT accounts_NNS for_IN any_DT liabilities_NNS which_WDT are_VBP expected_VBN to_TO materialise_VB from_IN such_JJ claims_NNS ._.
notes_NNS to_TO the_DT financial_JJ 68_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 21_CD Commitments_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000 000_CD 000_CD Capital_NN commitments_NNS Contracted_VBN for_IN but_CC not_RB provided_VBN in_IN the_DT accounts_NNS 197_CD 340_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS for_IN the_DT next_JJ year_NN Operating_VBG leases_NNS on_IN land_NN and_CC buildings_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 50_CD 187_CD 28_CD 21_CD In_IN two_CD to_TO five_CD years_NNS 707_CD 1,304_CD 566_CD 559_CD In_IN five_CD years_NNS or_CC more_JJR 1,816_CD 2,532_CD 2,573_CD 4,023_CD 594_CD 580_CD Other_JJ operating_NN leases_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 18_CD 42_CD 5_CD In_IN two_CD to_TO five_CD years_NNS 53_CD 47_CD 11_CD 17_CD In_IN five_CD years_NNS or_CC more_RBR 2_CD 71_CD 91_CD 16_CD 17_CD 22_CD Share_NN capital_NN Equity_NN share_NN capital_NN 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS 000_CD 000_CD Authorised_NNP Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 1,114,000,000_CD 1,114,000,000_CD 111,400_CD 111,400_CD Ordinary_NNP shares_NNS of_IN 10p_JJ each_DT Nominal_JJ value_NN Number_NNP 000_CD Issued_VBN ,_, allotted_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2001_CD 517,322,768_CD 51,732_CD Exercise_NN of_IN B_NNP Warrants_NNPS 22,008_CD 2_CD Exercise_NN of_IN share_NN options_NNS 736,644_CD 74_CD Exercise_NN of_IN DepoTech_NNP Warrants_NNPS 41,820_CD 4_CD Shares_NNS issued_VBN to_TO acquire_VB RTP_NNP Pharma_NNP Inc._NNP 41,900,099_CD 4,190_CD At_IN 31_CD December_NNP 2001_CD 560,023,339_CD 56,002_CD Exercise_NN of_IN B_NNP Warrants_NNPS 2,051,607_CD 205_CD Exercise_NN of_IN share_NN options_NNS 1,323,853_CD 133_CD Shares_NNP allocated_VBN in_IN respect_NN of_IN RTP_NNP Pharma_NNP Inc._NNP 8,059,268_CD 806_CD Issue_NN of_IN shares_NNS to_TO Kowa_NNP Company_NNP Limited_NNP 30,000,000_CD 3,000_CD Conversion_NNP of_IN Deferred_NNP A_NNP Shares_NNP 12,000,000_CD 1,200_CD At_IN 31_CD December_NNP 2002_CD 613,458,067_CD 61,346_CD SkyePharma_NNP achieved_VBD control_NN of_IN RTP_NNP Pharma_NNP Inc._NNP in_IN December_NNP 2001_CD when_WRB agreement_NN was_VBD reached_VBN to_TO acquire_VB the_DT majority_NN of_IN the_DT outstanding_JJ voting_NN shares_NNS in_IN RTP_NNP ._.
In_IN March_NNP 2002_CD SkyePharma_NNP announced_VBD the_DT acquisition_NN of_IN the_DT outstanding_JJ voting_NN shares_NNS in_IN RTP_NNP in_IN return_NN for_IN the_DT issue_NN of_IN SkyePharma_NNP Ordinary_NNP Shares_NNP ._.
The_DT total_JJ consideration_NN of_IN 39.4_CD million_CD including_VBG acquisition_NN costs_NNS comprised_VBD 49,959,367_CD Ordinary_NNP Shares_NNP and_CC 4.1_CD million_CD cash_NN ._.
69_CD 22_CD Share_NN capital_NN continued_VBD The_DT cash_NN consideration_NN received_VBN on_IN the_DT issue_NN of_IN Ordinary_NNP Shares_NNP during_IN the_DT year_NN amounted_VBD to_TO 26,168,000_CD 2001_CD :_: 468,000_CD ._.
Of_IN this_DT ,_, 30_CD million_CD Ordinary_NNP Shares_NNP were_VBD allotted_VBN to_TO Kowa_NNP Company_NNP Limited_NNP for_IN a_DT total_JJ consideration_NN of_IN 25.3_CD million_CD ._.
Following_VBG the_DT US_NNP launch_NN and_CC first_JJ commercial_JJ sale_NN of_IN Paxil_NNP CR_NNP by_IN GlaxoSmithKline_NNP in_IN April_NNP 2002_CD ,_, the_DT 12_CD million_CD Deferred_NNP A_NNP Shares_NNP were_VBD converted_VBN into_IN 12_CD million_CD Ordinary_NNP Shares_NNP ._.
Non-equity_JJ share_NN capital_NN 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS 000_CD 000_CD Authorised_VBN and_CC issued_VBN Deferred_NNP A_NNP Shares_NNP of_IN 10p_CD each_DT 12,000,000_CD 1,200_CD Deferred_JJ B_NNP Shares_NNP of_IN 10p_CD each_DT 12,000,000_CD 12,000,000_CD 1,200_CD 1,200_CD 12,000,000_CD 24,000,000_CD 1,200_CD 2,400_CD The_DT Deferred_JJ A_DT and_CC B_NNP Shares_NNP were_VBD issued_VBN to_TO Dr_NNP Gonella_NNP ,_, the_DT vendor_NN of_IN Jago_NNP ,_, on_IN 20_CD July_NNP 2000_CD under_IN the_DT Settlement_NNP Agreement_NN that_WDT established_VBD the_DT full_JJ and_CC final_JJ settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
The_DT holders_NNS of_IN Deferred_NNP A_NNP and_CC B_NNP Shares_NNP have_VBP no_DT rights_NNS to_TO participate_VB in_IN the_DT profits_NNS of_IN the_DT Company_NN ,_, no_DT voting_NN rights_NNS and_CC on_IN a_DT winding_VBG up_RP or_CC other_JJ return_NN of_IN capital_NN only_RB receive_VB the_DT nominal_JJ value_NN of_IN their_PRP$ shares_NNS if_IN the_DT holders_NNS of_IN Ordinary_NNP Shares_NNP in_IN the_DT capital_NN of_IN the_DT Company_NN have_VBP received_VBN the_DT sum_NN of_IN 1,000,000_CD per_IN Ordinary_NNP Share_NNP and_CC ,_, as_IN such_JJ ,_, are_VBP classified_VBN as_IN non-equity_JJ shares_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT Settlement_NNP Agreement_NNP ,_, following_VBG the_DT US_NNP launch_NN and_CC first_JJ commercial_JJ sale_NN of_IN Paxil_NNP CR_NNP by_IN GlaxoSmithKline_NNP in_IN April_NNP 2002_CD ,_, the_DT 12_CD million_CD Deferred_NNP A_NNP Shares_NNP were_VBD automatically_RB converted_VBN into_IN 12_CD million_CD Ordinary_NNP Shares_NNP ._.
The_DT 12_CD million_CD Deferred_NNP B_NNP Shares_NNP automatically_RB convert_VBP to_TO 12_CD million_CD Ordinary_NNP Shares_NNP on_IN the_DT Companys_NNP receipt_NN of_IN a_DT royalty_NN statement_NN under_IN the_DT current_JJ Licence_NNP Agreement_NNP stating_VBG that_IN reported_VBD sales_NNS of_IN Paroxetine_NNP Paxil_NNP in_IN combination_NN with_IN the_DT GEOMATRIX_NNP technology_NN have_VBP exceeded_VBN $_$ 1,000_CD million_CD during_IN any_DT calendar_NN period_NN prior_RB to_TO 1_CD January_NNP 2006_CD or_CC exceeded_VBD $_$ 337_CD million_CD between_IN 1_CD January_NNP 2006_CD and_CC 3_CD May_NNP 2006_CD ._.
In_IN the_DT event_NN that_IN this_DT condition_NN is_VBZ not_RB satisfied_JJ prior_RB to_TO 3_CD May_NNP 2006_CD ,_, the_DT Deferred_NNP B_NNP Shares_NNP will_MD not_RB be_VB converted_VBN and_CC will_MD be_VB canceled_VBN ._.
The_DT vendor_NN will_MD not_RB be_VB entitled_VBN to_TO any_DT other_JJ compensation_NN nor_CC additional_JJ compensation_NN ._.
The_DT Deferred_JJ A_DT and_CC B_NNP Shares_NNP were_VBD issued_VBN on_IN 20_CD July_NNP 2000_CD when_WRB the_DT price_NN of_IN an_DT Ordinary_NNP Share_NN was_VBD 94.25_CD pence_NN ._.
The_DT difference_NN between_IN the_DT nominal_JJ value_NN of_IN the_DT Deferred_NNP B_NNP Shares_NNP and_CC their_PRP$ fair_JJ value_NN ,_, taken_VBN to_TO be_VB 94.25_CD pence_NNS ,_, at_IN issue_NN has_VBZ been_VBN recorded_VBN as_IN non-equity_JJ share_NN premium_NN ._.
Warrants_NNS The_DT Company_NN has_VBZ the_DT following_JJ warrants_NNS outstanding_JJ :_: a_DT B_NNP Warrants_NNPS Number_NNP At_IN 1_CD January_NNP 2002_CD 56,525,415_CD Warrants_NNS exercised_VBN 20,516,073_CD Warrants_NNS lapsed_VBD 36,009,342_CD At_IN 31_CD December_NNP 2002_CD The_DT B_NN Warrants_NNS ,_, which_WDT were_VBD issued_VBN in_IN January_NNP 1996_CD on_IN the_DT basis_NN of_IN one_CD warrant_NN for_IN every_DT ten_NN existing_VBG Ordinary_NNP Shares_NNP subscribed_VBD pursuant_JJ to_TO the_DT placing_NN ,_, rights_NNS issue_NN and_CC capitalization_NN of_IN loan_NN notes_NNS and_CC in_IN consideration_NN for_IN the_DT outstanding_JJ warrants_NNS of_IN Krypton_NNP ,_, entitled_VBD the_DT holders_NNS to_TO subscribe_VB for_IN Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN beginning_VBG six_CD months_NNS after_IN the_DT date_NN of_IN issue_NN and_CC ending_VBG on_IN 31_CD December_NNP 2002_CD at_IN an_DT effective_JJ price_NN of_IN 40_CD pence_NN per_IN Ordinary_NNP Share_NNP based_VBN on_IN ten_JJ warrants_NNS ._.
Consequent_JJ upon_IN the_DT consolidation_NN of_IN existing_VBG Ordinary_NNP Shares_NNP in_IN May_NNP 1996_CD the_DT terms_NNS under_IN which_WDT the_DT B_NNP Warrants_NNS may_MD be_VB exercised_VBN were_VBD amended_VBN so_RB that_IN a_DT holder_NN was_VBD required_VBN to_TO exercise_VB ten_NN B_NNP Warrants_NNS to_TO acquire_VB one_CD Ordinary_NNP Share_NN ._.
All_DT outstanding_JJ B_NNP Warrants_NNS lapsed_VBD on_IN 31_CD December_NNP 2002_CD and_CC so_RB the_DT market_NN value_NN of_IN B_NNP Warrants_NNS as_IN at_IN 31_CD December_NNP 2002_CD was_VBD nil_CD pence_NN 31_CD December_NNP 2001_CD :_: 3.25_CD pence_NN ._.
The_DT market_NN value_NN of_IN B_NNP Warrants_NNS during_IN the_DT period_NN from_IN 1_CD January_NNP 2002_CD to_TO 31_CD December_NNP 2002_CD ranged_VBD from_IN the_DT lowest_JJS mid-price_NN of_IN nil_NN pence_NN to_TO the_DT highest_JJS mid-price_NN of_IN 4.75_CD pence_NN per_IN B_NNP Warrant_NNP ._.
notes_NNS to_TO the_DT financial_JJ 70_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 22_CD Share_NN capital_NN continued_VBD b_NN D_NNP and_CC E_NNP Warrants_NNPS The_DT D_NNP and_CC E_NNP Warrants_NNS were_VBD issued_VBN in_IN March_NNP 2002_CD as_IN part_NN of_IN the_DT consideration_NN for_IN the_DT agreement_NN with_IN Paul_NNP Capital_NNP to_TO fund_VB new_JJ product_NN development_NN ._.
The_DT D_NNP and_CC E_NNP Warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 5_CD million_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN to_TO 31_CD December_NNP 2008_CD at_IN an_DT exercise_NN price_NN of_IN 73.75_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 0.3_CD million_CD has_VBZ been_VBN attributed_VBN to_TO the_DT D_NNP and_CC E_NNP Warrants_NNS which_WDT has_VBZ been_VBN recorded_VBN within_IN Other_JJ Reserves_NNS ._.
c_NN Other_JJ Warrants_NNS Warrants_NNS were_VBD issued_VBN in_IN December_NNP 1999_CD as_IN part_NN of_IN the_DT acquisition_NN of_IN DepoTech_NNP and_CC entitle_VB the_DT holders_NNS to_TO subscribe_VB for_IN 291,777_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN beginning_VBG 31_CD December_NNP 1999_CD and_CC ending_VBG on_IN 25_CD February_NNP 2005_CD at_IN an_DT exercise_NN price_NN of_IN $_$ 1.453_CD 90.25_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
Share_NN options_NNS The_DT Company_NN encourages_VBZ employee_NN participation_NN in_IN its_PRP$ shares_NNS through_IN ownership_NN and_CC continues_VBZ to_TO operate_VB various_JJ Share_NN Option_NN Schemes_NNS and_CC the_DT Unapproved_NNP Share_NN Option_NN Scheme_NN ._.
Under_IN the_DT terms_NNS of_IN these_DT Schemes_NNS the_DT Board_NNP may_MD offer_VB options_NNS to_TO purchase_VB Ordinary_NNP Shares_NNP in_IN the_DT Company_NN to_TO employees_NNS ,_, including_VBG Directors_NNS ,_, at_IN a_DT price_NN not_RB less_JJR than_IN the_DT higher_JJR of_IN the_DT nominal_JJ value_NN and_CC the_DT market_NN value_NN of_IN the_DT shares_NNS ._.
Options_NNS granted_VBN to_TO UK_NNP and_CC European_JJ employees_NNS are_VBP only_RB exercisable_JJ between_IN the_DT third_JJ and_CC tenth_NN anniversary_NN of_IN the_DT date_NN of_IN grant_NN ,_, and_CC are_VBP subject_JJ to_TO the_DT Companys_NNP Code_NNP of_IN Conduct_NNP for_IN dealing_VBG in_IN Shares_NNP ,_, and_CC the_DT Model_NNP Code_NNP ._.
Options_NNS granted_VBN to_TO US_NNP employees_NNS prior_RB to_TO 2001_CD vest_NN at_IN 25_CD %_NN per_IN annum_NN from_IN the_DT date_NN of_IN grant_NN and_CC there_EX were_VBD no_DT performance_NN criteria_NNS ._.
UK_NNP and_CC European_JJ options_NNS may_MD only_RB be_VB exercised_VBN if_IN the_DT growth_NN in_IN the_DT Companys_NNP share_NN price_NN over_IN a_DT consecutive_JJ three-year_JJ period_NN exceeds_VBZ the_DT growth_NN over_IN the_DT same_JJ period_NN in_IN the_DT FT-SE_NNP All_NNP Share_NNP Index_NNP for_IN options_NNS granted_VBN prior_RB to_TO 2001_CD ._.
This_DT criteria_NNS was_VBD satisfied_VBN for_IN the_DT first_JJ time_NN in_IN March_NNP 2000_CD ._.
Employees_NNS with_IN options_NNS that_WDT are_VBP within_IN their_PRP$ exercise_NN period_NN are_VBP now_RB able_JJ to_TO exercise_VB those_DT options_NNS within_IN any_DT one-year_JJ period_NN from_IN the_DT date_NN the_DT performance_NN condition_NN is_VBZ satisfied_VBN ._.
Super_NNP Options_NNPS are_VBP exercisable_JJ after_IN five_CD years_NNS and_CC are_VBP subject_JJ to_TO higher_JJR performance_NN conditions_NNS in_IN accordance_NN with_IN those_DT recommended_VBN by_IN the_DT Association_NNP of_IN British_NNP Insurers_NNP ._.
Following_VBG changes_NNS to_TO the_DT option_NN plans_VBZ approved_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG June_NNP 2001_CD ,_, options_NNS granted_VBD since_IN that_DT date_NN to_TO Directors_NNS and_CC senior_JJ employees_NNS are_VBP subject_JJ to_TO performance_NN conditions_NNS linked_VBN to_TO the_DT total_JJ shareholder_NN return_NN of_IN a_DT comparator_NN group_NN of_IN companies_NNS ,_, and_CC are_VBP not_RB subject_JJ to_TO retesting_VBG ._.
Options_NNS granted_VBN to_TO other_JJ US_NNP employees_NNS continue_VBP to_TO vest_NN at_IN 25_CD %_NN per_IN annum_NN with_IN no_DT performance_NN criteria_NNS ,_, and_CC other_JJ European_JJ employees_NNS who_WP are_VBP not_RB Directors_NNS or_CC senior_JJ employees_NNS can_MD exercise_VB their_PRP$ options_NNS after_IN three_CD years_NNS and_CC are_VBP not_RB subject_JJ to_TO performance_NN conditions_NNS ._.
The_DT Groups_NNS plans_NNS are_VBP further_JJ detailed_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
The_DT market_NN value_NN of_IN Ordinary_NNP Shares_NNP during_IN 2002_CD ranged_VBD from_IN the_DT lowest_JJS closing_NN mid-price_NN of_IN 39.0_CD pence_NN to_TO the_DT highest_JJS closing_NN mid-price_NN of_IN 80.25_CD pence_NN per_IN share_NN ._.
71_CD 22_CD Share_NN capital_NN continued_VBD At_IN 31_CD December_NNP 2002_CD the_DT following_VBG Ordinary_NNP Shares_NNP were_VBD under_IN option_NN to_TO employees_NNS or_CC former_JJ employees_NNS of_IN the_DT Group_NNP :_: Option_NN price_NN for_IN each_DT Number_NN of_IN options_NNS over_IN Ordinary_NNP Share_NN of_IN 10p_CD Ordinary_NNP shares_NNS of_IN 10p_CD Expiry_NNP date_NN 75.0_CD p_NN 1,427,676_CD 29_CD April_NNP 2006_CD 92.0_CD p_NN 417,255_CD 28_CD May_NNP 2006_CD 81.0_CD p_NN 1,234,568_CD 6_CD December_NNP 2006_CD 66.5_CD p_NN 646,281_CD 7_CD April_NNP 2007_CD 51.0_CD p_NN 124,073_CD 28_CD January_NNP 2008_CD 93.0_CD p_NN 796,362_CD 31_CD March_NNP 2008_CD 44.8_CD p_NN 1,464,612_CD 5_CD October_NNP 2008_CD 69.5_CD p_NN 3,232,813_CD 19_CD April_NNP 2009_CD 56.7_CD p_NN 8,421,310_CD 25_CD May_NNP 2009_CD 56.9_CD p_NN 238,066_CD 7_CD September_NNP 2009_CD 91.3_CD p_NN 1,036,268_CD 6_CD June_NNP 2010_CD 81.7_CD p_NN 1,853,441_CD 3_CD November_NNP 2010_CD 80.6_CD p_NN 6,602,439_CD 12_CD June_NNP 2011_CD 55.6_CD p_NN 1,318,008_CD 31_CD October_NNP 2011_CD 55.1_CD p_NN 552,514_CD 24_CD December_NNP 2011_CD 72.3_CD p_NN 9,147,254_CD 12_CD April_NNP 2012_CD 78.6_CD p_NN 515,653_CD 24_CD May_NNP 2012_CD 51.7_CD p_NN 1,428,340_CD 25_CD September_NNP 2012_CD 23_CD Shares_NNP and_CC warrants_NNS to_TO be_VB issued_VBN Group_NNP and_CC Company_NNP 000_CD At_IN 1_CD January_NNP 2002_CD 10,617_CD Goodwill_NNP adjustments_NNS on_IN deferred_JJ consideration_NN 4,837_CD Shares_NNP allocated_VBN in_IN respect_NN of_IN RTP_NNP Pharma_NNP Inc._NNP 5,780_CD At_IN 31_CD December_NNP 2002_CD a_DT Krypton_NNP The_NNP deferred_JJ consideration_NN on_IN the_DT acquisition_NN of_IN Krypton_NNP was_VBD revised_VBN in_IN April_NNP 1996_CD ,_, such_JJ that_IN a_DT maximum_NN of_IN 37.5_CD million_CD Ordinary_NNP Shares_NNP would_MD be_VB issued_VBN contingent_NN on_IN a_DT change_NN in_IN control_NN of_IN the_DT Company_NN at_IN a_DT share_NN price_NN of_IN not_RB less_JJR than_IN 80_CD pence_NNS compounded_VBN at_IN an_DT annual_JJ rate_NN of_IN 10_CD %_NN ,_, or_CC satisfaction_NN of_IN the_DT following_JJ conditions_NNS and_CC hurdles_NNS :_: i_FW 2.5_CD million_CD Ordinary_NNP Shares_NNP on_IN each_DT Krypton_NNP product_NN obtaining_VBG ANDA_NNP approval_NN before_IN 31_CD December_NNP 2003_CD ,_, subject_JJ to_TO a_DT maximum_NN of_IN 7.5_CD million_CD Ordinary_NNP shares_NNS ._.
ii_FW an_DT additional_JJ 10_CD million_CD Ordinary_NNP Shares_NNP in_IN the_DT event_NN that_IN the_DT aggregate_JJ annual_JJ sales_NNS of_IN the_DT Krypton_NNP products_NNS exceeds_VBZ $_$ 50_CD million_CD and_CC the_DT Company_NN is_VBZ profitable_JJ in_IN respect_NN of_IN these_DT products_NNS before_IN 31_CD December_NNP 2003_CD :_: iii_FW an_DT additional_JJ 10_CD million_CD Ordinary_NNP Shares_NNP in_IN the_DT event_NN that_IN the_DT aggregate_JJ annual_JJ sales_NNS of_IN the_DT Krypton_NNP products_NNS and_CC annual_JJ revenues_NNS of_IN the_DT Company_NN exceeds_VBZ $_$ 200_CD million_CD and_CC the_DT Company_NN is_VBZ profitable_JJ in_IN respect_NN of_IN these_DT products_NNS before_IN 31_CD December_NNP 2003_CD :_: iv_VB an_DT additional_JJ 10_CD million_CD Ordinary_NNP Shares_NNP in_IN the_DT event_NN that_IN the_DT aggregate_JJ annual_JJ sales_NNS of_IN the_DT Krypton_NNP products_NNS and_CC annual_JJ revenues_NNS of_IN the_DT Company_NN exceeds_VBZ $_$ 275_CD million_CD and_CC the_DT Company_NN is_VBZ profitable_JJ in_IN respect_NN of_IN these_DT products_NNS before_IN 31_CD December_NNP 2003_CD ._.
In_IN the_DT event_NN that_IN two_CD of_IN hurdles_NNS ii_FW ,_, iii_NN and_CC iv_NN are_VBP satisfied_VBN in_IN relation_NN to_TO any_DT single_JJ years_NNS sales_NNS ,_, only_RB the_DT first_JJ such_JJ hurdle_NN will_MD be_VB considered_VBN as_IN having_VBG been_VBN satisfied_VBN ._.
notes_NNS to_TO the_DT financial_JJ 72_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 23_CD Shares_NNP and_CC warrants_NNS to_TO be_VB issued_VBN continued_VBN Certain_NNP of_IN the_DT hurdles_NNS relating_VBG to_TO the_DT Krypton_NNP acquisition_NN were_VBD not_RB formulated_VBN to_TO take_VB account_NN of_IN the_DT detailed_JJ arrangements_NNS currently_RB envisaged_VBN by_IN the_DT Company_NN ._.
Should_MD the_DT annual_JJ revenues_NNS of_IN the_DT Company_NN approach_NN the_DT amounts_NNS specified_VBN in_IN hurdles_NNS iii_NN and_CC iv_NN ,_, SkyePharma_NNP may_MD need_VB to_TO renegotiate_VB elements_NNS of_IN the_DT Krypton_NNP acquisition_NN agreement_NN ._.
As_IN no_DT Krypton_NN products_NNS are_VBP marketed_VBN and_CC no_DT licensing_NN partners_NNS have_VBP been_VBN identified_VBN for_IN the_DT products_NNS the_DT Directors_NNS have_VBP taken_VBN the_DT view_NN that_IN the_DT above_JJ hurdles_NNS can_MD no_RB longer_RB be_VB reasonably_RB expected_VBN to_TO be_VB met_VBN ._.
Consequently_RB no_DT provision_NN for_IN deferred_JJ consideration_NN has_VBZ been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2002_CD ._.
b_NN RTP_NNP As_IN part_NN of_IN the_DT RTP_NNP acquisition_NN deferred_VBD consideration_NN may_MD be_VB due_JJ to_TO the_DT former_JJ RTP_NNP shareholders_NNS in_IN consideration_NN for_IN the_DT loss_NN of_IN certain_JJ option_NN rights_NNS ._.
If_IN the_DT SkyePharma_NNP share_NN price_NN is_VBZ below_IN 82_CD pence_NN on_IN 30_CD June_NNP 2003_CD ,_, then_RB the_DT Company_NN is_VBZ required_VBN to_TO issue_VB 200,000_CD additional_JJ shares_NNS ,_, or_CC pay_VB an_DT amount_NN in_IN cash_NN ,_, for_IN each_DT penny_NN difference_NN between_IN the_DT actual_JJ share_NN price_NN and_CC 82_CD pence_NN ._.
In_IN the_DT opinion_NN of_IN the_DT Directors_NNS ,_, the_DT outcome_NN can_MD not_RB be_VB estimated_VBN with_IN any_DT degree_NN of_IN certainty_NN ._.
Therefore_RB this_DT deferred_JJ consideration_NN has_VBZ not_RB been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2002_CD ._.
c_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP In_IN March_NNP 2002_CD the_DT Group_NNP announced_VBD a_DT second_JJ transaction_NN with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP under_IN which_WDT SkyePharma_NNP will_MD issue_VB Ordinary_NNP Shares_NNP up_IN to_TO a_DT value_NN of_IN $_$ 7.5_CD million_CD if_IN royalties_NNS and_CC milestones_NNS received_VBN by_IN SkyePharma_NNP in_IN respect_NN of_IN those_DT products_NNS included_VBD in_IN the_DT transaction_NN are_VBP not_RB in_IN excess_NN of_IN minimum_JJ annual_JJ payments_NNS required_VBN to_TO be_VB made_VBN by_IN Paul_NNP Capital_NNP ._.
During_IN 2002_CD the_DT royalties_NNS received_VBN by_IN SkyePharma_NNP were_VBD substantially_RB in_IN excess_NN of_IN the_DT minimum_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ,_, consequently_RB the_DT company_NN has_VBZ not_RB provided_VBN for_IN any_DT additional_JJ obligations_NNS under_IN this_DT provision_NN ._.
24_CD Reserves_NNS Equity_NN Non-equity_NN Profit_NN and_CC share_NN share_NN Other_JJ loss_NN premium_NN premium_NN reserves_NNS account_VBP Group_NNP 000 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 267,137_CD 20,220_CD 10,720_CD 271,951_CD Exchange_NNP adjustments_NNS 903_CD On_IN issue_NN of_IN shares_NNS and_CC warrants_NNS 37,366_CD 10,110_CD 311_CD On_IN exercise_NN of_IN share_NN options_NNS 567_CD On_IN exercise_NN of_IN warrants_NNS 1,239_CD 624_CD On_IN lapse_NN of_IN warrants_NNS 1,096_CD 1,096_CD Goodwill_NNP adjustments_NNS on_IN deferred_JJ consideration_NN 4,837_CD Profit_NN for_IN the_DT year_NN 1,109_CD At_IN 31_CD December_NNP 2002_CD 306,309_CD 10,110_CD 9,311_CD 264,006_CD Other_JJ reserves_NNS relate_VBP to_TO a_DT merger_NN reserve_NN on_IN acquisition_NN and_CC a_DT warrant_NN reserve_NN on_IN the_DT issue_NN of_IN the_DT D_NNP and_CC E_NNP Warrants_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD the_DT cumulative_JJ amount_NN of_IN goodwill_NN eliminated_VBN against_IN reserves_NNS was_VBD 147,632,000_CD 2001_CD :_: 152,469,000_CD ._.
Equity_NN Non-equity_NN Profit_NN and_CC share_NN share_NN Other_JJ loss_NN premium_NN premium_NN reserves_NNS account_VBP Company_NN 000 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 267,137_CD 20,220_CD 10,720_CD 16,494_CD On_IN issue_NN of_IN shares_NNS and_CC warrants_NNS 37,366_CD 10,110_CD 311_CD On_IN exercise_NN of_IN share_NN options_NNS 567_CD On_IN exercise_NN of_IN warrants_NNS 1,239_CD 624_CD On_IN lapse_NN of_IN warrants_NNS 1,096_CD Profit_NN for_IN the_DT year_NN 146_CD At_IN 31_CD December_NNP 2002_CD 306,309_CD 10,110_CD 9,311_CD 16,348_CD As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Profit_NN and_CC Loss_NN Account_NNP of_IN the_DT Company_NN is_VBZ not_RB presented_VBN ._.
The_DT profit_NN attributable_JJ to_TO shareholders_NNS dealt_VBN with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN is_VBZ 146,000_CD 2001_CD :_: 1,269,000_CD ._.
73_CD 25_CD Financial_NNP instruments_NNS The_DT Group_NNP holds_VBZ financial_JJ instruments_NNS to_TO finance_VB its_PRP$ operations_NNS and_CC to_TO manage_VB the_DT currency_NN risk_NN that_WDT arises_VBZ from_IN these_DT operations_NNS ._.
The_DT Group_NNP finances_VBZ its_PRP$ operations_NNS through_IN a_DT combination_NN of_IN shareholders_NNS funds_NNS ,_, convertible_JJ bonds_NNS ,_, bank_NN loans_NNS and_CC other_JJ borrowings_NNS ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT groups_NNS financial_JJ instruments_NNS are_VBP liquidity_NN risk_NN ,_, foreign_JJ currency_NN risk_NN ,_, interest_NN rate_NN risk_NN and_CC credit_NN risk_NN ._.
Liquidity_NN risks_NNS The_DT Groups_NNS policy_NN is_VBZ to_TO maintain_VB continuity_NN of_IN funding_VBG through_IN a_DT mixture_NN of_IN long-term_JJ debt_NN and_CC bank_NN loans_NNS ,_, raised_VBD to_TO cover_VB specific_JJ projects_NNS ,_, and_CC through_IN the_DT issue_NN of_IN shares_NNS to_TO collaborative_JJ partners_NNS ,_, where_WRB necessary_JJ ,_, to_TO finance_VB development_NN contracts_NNS ._.
Short-term_JJ flexibility_NN is_VBZ provided_VBN through_IN the_DT use_NN of_IN overdrafts_NNS ._.
The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS debt_NN is_VBZ set_VBN out_RP below_IN at_IN note_NN c._NN Foreign_JJ currency_NN risk_NN All_DT of_IN the_DT Groups_NNS operations_NNS are_VBP based_VBN overseas_RB in_IN Continental_NNP Europe_NNP and_CC North_NNP America_NNP giving_VBG rise_NN to_TO exposures_NNS to_TO changes_NNS in_IN foreign_JJ exchange_NN rates_NNS notably_RB the_DT Swiss_JJ Franc_NN ,_, Euro_NNP ,_, Swedish_NNP Krona_NNP ,_, US_NNP Dollar_NNP and_CC Canadian_NNP Dollar_NNP ._.
To_TO minimize_VB the_DT impact_NN of_IN any_DT fluctuations_NNS ,_, the_DT Groups_NNS policy_NN has_VBZ historically_RB been_VBN to_TO maintain_VB natural_JJ hedges_NNS by_IN relating_VBG the_DT structure_NN of_IN borrowings_NNS to_TO the_DT trading_NN cash_NN flows_VBZ that_IN generate_VB them_PRP ._.
Where_WRB subsidiaries_NNS are_VBP funded_VBN centrally_RB ,_, this_DT is_VBZ achieved_VBN by_IN the_DT use_NN of_IN long-term_JJ loans_NNS the_DT exchange_NN differences_NNS on_IN which_WDT are_VBP taken_VBN to_TO reserves_NNS ._.
Where_WRB it_PRP was_VBD not_RB possible_JJ to_TO use_VB natural_JJ hedges_NNS ,_, currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS were_VBD used_VBN ._.
The_DT Group_NNP has_VBZ used_VBN these_DT financial_JJ instruments_NNS during_IN the_DT year_NN to_TO minimize_VB the_DT currency_NN exposure_NN on_IN operational_JJ transactions_NNS ._.
Foreign_JJ currency_NN exchange_NN movements_NNS did_VBD not_RB have_VB a_DT material_NN impact_NN on_IN the_DT results_NNS of_IN operations_NNS in_IN 2002_CD compared_VBN with_IN 2001_CD ._.
Interest_NN rate_NN risk_NN The_DT Group_NNP borrows_VBZ at_IN fixed_VBN and_CC floating_VBG rates_NNS of_IN interest_NN as_IN deemed_VBN appropriate_JJ for_IN its_PRP$ circumstances_NNS ._.
Where_WRB necessary_JJ the_DT Group_NNP uses_VBZ several_JJ interest_NN rate_NN swaps_NNS to_TO achieve_VB the_DT desired_VBN interest_NN rate_NN profile_NN ._.
During_IN the_DT year_NN the_DT Group_NNP had_VBD several_JJ cancellable_JJ ,_, floating_VBG rate_NN ,_, interest_NN rate_NN swaps_NNS on_IN 30_CD million_CD of_IN the_DT 6_CD %_NN convertible_JJ bond_NN liability_NN ._.
The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS is_VBZ set_VBN out_RP in_IN notes_NNS a_DT and_CC b_NN respectively_RB ._.
Credit_NNP risk_NN The_NNP Group_NNP is_VBZ exposed_VBN to_TO credit_NN related_VBN losses_NNS in_IN the_DT event_NN of_IN non-performance_JJ by_IN third_JJ parties_NNS to_TO financial_JJ instruments_NNS ._.
The_DT Group_NNP does_VBZ not_RB expect_VB any_DT third_JJ parties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS given_VBN the_DT policy_NN of_IN selecting_VBG only_RB parties_NNS with_IN high_JJ credit_NN ratings_NNS and_CC minimizing_VBG its_PRP$ exposure_NN to_TO any_DT one_CD institution_NN ._.
In_IN the_DT numerical_JJ disclosures_NNS that_WDT follow_VBP ,_, short-term_JJ debtors_NNS and_CC creditors_NNS that_WDT arise_VBP directly_RB as_IN a_DT result_NN of_IN the_DT Groups_NNS operations_NNS are_VBP excluded_VBN from_IN all_DT disclosures_NNS with_IN the_DT exception_NN of_IN note_NN f_SYM on_IN currency_NN exposures_NNS ._.
a_DT Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ assets_NNS 31_CD December_NNP 2002_CD Non-interest_JJ Floating_VBG rate_NN Fixed_VBN rate_NN bearing_VBG Total_JJ financial_JJ financial_JJ assets_NNS financial_JJ assets_NNS financial_JJ assets_NNS assets_NNS Currency_NNP 000 000 000 000_CD Sterling_NNP 18,680_CD 1,961_CD 36_CD 20,677_CD $_$ US_PRP 4,292_CD 16,663_CD 20,955_CD Swiss_JJ francs_NNS 1,870_CD 1,870_CD $_$ Canadian_JJ 2,026_CD 2,228_CD 4,254_CD Euro_NNP 617_CD 617_CD Swedish_NNP Krona_NNP 523_CD 523_CD 28,008_CD 1,961_CD 18,927_CD 48,896_CD Total_JJ financial_JJ assets_NNS comprise_VBP fixed_VBN asset_NN investments_NNS of_IN 18.9_CD million_CD 2001_CD :_: 13.7_CD million_CD ,_, current_JJ asset_NN investments_NNS of_IN 2.0_CD million_CD 2001_CD :_: nil_NN and_CC cash_NN and_CC short-term_JJ bank_NN deposits_NNS of_IN 28.1_CD million_CD 2001_CD :_: 26.9_CD million_CD ._.
Floating_VBG rate_NN financial_JJ assets_NNS bear_VBP interest_NN at_IN rates_NNS based_VBN upon_IN the_DT floating_VBG bank_NN rate_NN in_IN the_DT country_NN in_IN which_WDT the_DT funds_NNS are_VBP held_VBN ._.
The_DT weighted_JJ average_JJ interest_NN rate_NN on_IN fixed_JJ rate_NN financial_JJ assets_NNS is_VBZ 5_CD %_NN 2001_CD :_: 2_CD %_NN ._.
The_DT weighted_JJ average_JJ time_NN for_IN which_WDT the_DT rate_NN is_VBZ fixed_VBN is_VBZ 54_CD months_NNS 2001_CD :_: 4_CD months_NNS ._.
notes_NNS to_TO the_DT financial_JJ 74_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 25_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2001_CD Non-interest_JJ Floating_VBG rate_NN Fixed_VBN rate_NN bearing_VBG Total_JJ financial_JJ financial_JJ assets_NNS financial_JJ assets_NNS financial_JJ assets_NNS assets_NNS Currency_NNP 000 000 000 000_CD Sterling_NNP 5,690_CD 62_CD 5,752_CD $_$ US_PRP 14,977_CD 11,467_CD 26,444_CD Swiss_JJ francs_NNS 549_CD 93_CD 642_CD $_$ Canadian_JJ 48_CD 5,389_CD 2,228_CD 7,665_CD Euro_NNP 48_CD 48_CD 21,312_CD 5,389_CD 13,850_CD 40,551_CD b_NN Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ liabilities_NNS Weighted_VBN average_JJ 31_CD December_NNP 2002_CD interest_NN rate_NN Weighted_JJ Non-interest_JJ Fixed_JJ rate_NN on_IN fixed_VBN average_JJ time_NN Floating_VBG rate_NN bearing_NN Weighted_NNP Total_NNP financial_JJ financial_JJ for_IN which_WDT rate_NN financial_JJ financial_JJ average_JJ time_NN financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS liabilities_NNS to_TO maturity_NN liabilities_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 29,400_CD 6.00_CD 29.5_CD 30,000_CD 11,310_CD 40.0_CD 70,710_CD Swiss_JJ francs_NNS 4,560_CD 3.64_CD 13.5_CD 4,897_CD 9,457_CD Euro_NNP 863_CD 6.25_CD 11.0_CD 201_CD 417.0_CD 1,064_CD $_$ US_PRP 25_CD 5.25_CD 40.0_CD 621_CD 3,269_CD 144.0_CD 3,915_CD Swedish_NNP Krona_NNP 319_CD 7.25_CD 27.8_CD 319_CD 35,167_CD 5.71_CD 27.0_CD 35,518_CD 14,780_CD 68.1_CD 85,465_CD Financial_NNP liabilities_NNS comprise_VBP total_JJ borrowings_NNS of_IN 10.0_CD million_CD 2001_CD :_: 14.4_CD million_CD ,_, convertible_JJ bonds_NNS of_IN 59.4_CD million_CD 2001_CD :_: 59.4_CD million_CD ,_, non-equity_JJ Deferred_NNP A_NNP and_CC B_NNP Shares_NNP of_IN 11.3_CD million_CD 2001_CD :_: 22.6_CD million_CD ,_, other_JJ creditors_NNS of_IN 4.6_CD million_CD 2001_CD :_: 5.1_CD million_CD and_CC provisions_NNS of_IN 0.2_CD million_CD 2001_CD :_: 0.1_CD million_CD ._.
Total_JJ financial_JJ liabilities_NNS does_VBZ not_RB agree_VB to_TO the_DT total_NN of_IN the_DT balance_NN sheet_NN captions_NNS due_JJ to_TO the_DT presence_NN of_IN 1,023,000_CD 2001_CD :_: 1,438,000_CD of_IN unamortised_JJ issue_NN costs_NNS within_IN the_DT value_NN shown_VBN on_IN the_DT balance_NN sheet_NN for_IN convertible_JJ bonds_NNS ._.
All_DT floating_VBG rate_NN financial_JJ liabilities_NNS ,_, in_IN both_DT 2002_CD and_CC 2001_CD ,_, are_VBP interest_NN bearing_NN financial_JJ liabilities_NNS that_WDT bear_VBP interest_NN at_IN interest_NN rates_NNS based_VBN on_IN LIBOR_NNP ,_, prime_JJ and_CC other_JJ bank_NN based_VBN lending_NN rates_NNS in_IN the_DT country_NN in_IN which_WDT the_DT liability_NN arises_VBZ ,_, which_WDT are_VBP fixed_VBN for_IN periods_NNS of_IN up_RB to_TO 12_CD months_NNS ._.
31_CD December_NNP 2001_CD Weighted_JJ average_JJ interest_NN rate_NN Weighted_JJ Non-interest_JJ Fixed_JJ rate_NN on_IN fixed_VBN average_JJ time_NN Floating_VBG rate_NN bearing_NN Weighted_NNP Total_NNP financial_JJ financial_JJ for_IN which_WDT rate_NN financial_JJ financial_JJ average_JJ time_NN financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS liabilities_NNS to_TO maturity_NN liabilities_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 59,400_CD 6.00_CD 41.5_CD 22,623_CD 52.0_CD 82,023_CD Swiss_JJ francs_NNS 4,302_CD 3.63_CD 23.6_CD 5,548_CD 9,850_CD French_JJ Francs_NNS 1,599_CD 6.25_CD 23.0_CD 745_CD 65_CD 419.0_CD 2,409_CD $_$ US_PRP 3,898_CD 3,385_CD 156.0_CD 7,283_CD 65,301_CD 5.85_CD 39.9_CD 10,191_CD 26,073_CD 66.4_CD 101,565_CD 75_CD 25_CD Financial_NNP instruments_NNS continued_VBD c_NN Maturity_NN of_IN financial_JJ liabilities_NNS 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Within_IN one_CD year_NN 2,927_CD 7,257_CD Between_IN one_CD and_CC two_CD years_NNS 5,256_CD 24,513_CD Between_IN two_CD and_CC five_CD years_NNS 71,587_CD 64,009_CD Beyond_NNP five_CD years_NNS 5,695_CD 5,786_CD 85,465_CD 101,565_CD d_SYM Borrowing_VBG facilities_NNS As_IN at_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD the_DT following_VBG undrawn_JJ committed_JJ borrowing_NN facilities_NNS available_JJ ._.
31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Expiring_VBG within_IN one_CD year_NN 1,646_CD 369_CD e_SYM Fair_NNP values_VBZ The_DT comparison_NN of_IN fair_JJ and_CC book_NN values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ instruments_NNS as_IN at_IN 31_CD December_NNP 2002_CD is_VBZ set_VBN out_RP below_IN ._.
Market_NN value_NN or_CC Directors_NNS valuation_NN have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN fixed_VBN and_CC current_JJ asset_NN investments_NNS ._.
Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ values_NNS of_IN all_DT swaps_NNS and_CC foreign_JJ currency_NN contracts_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT non-equity_JJ Deferred_NNP B_NNP Shares_NNP has_VBZ been_VBN calculated_VBN by_IN reference_NN to_TO the_DT Ordinary_NNP Share_NN price_NN at_IN 31_CD December_NNP 2002_CD ,_, based_VBN upon_IN the_DT Directors_NNS opinion_NN that_WDT 12_CD million_CD Ordinary_NNP Shares_NNP will_MD be_VB issued_VBN in_IN settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
See_VB note_NN 22_CD :_: Share_NN capital_NN ,_, for_IN details_NNS of_IN the_DT contingencies_NNS that_WDT shall_MD determine_VB the_DT issuance_NN of_IN the_DT Ordinary_NNP Shares_NNP ._.
The_DT fair_JJ values_NNS of_IN all_DT other_JJ items_NNS have_VBP been_VBN calculated_VBN by_IN discounting_VBG future_JJ cash_NN flows_VBZ at_IN interest_NN rates_NNS prevailing_VBG at_IN 31_CD December_NNP 2002_CD ._.
31_CD December_NNP 2002_CD Book_NNP values_NNS Fair_NNP values_VBZ Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS 000_CD 000_CD Fixed_VBN asset_NN investments_NNS 18,874_CD 17,287_CD Current_JJ asset_NN investments_NNS 1,961_CD 1,961_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 7,394_CD 7,394_CD Short-term_JJ bank_NN deposits_NNS 20,667_CD 20,667_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long-term_JJ borrowings_NNS 2,927_CD 2,927_CD Long-term_JJ convertible_JJ debt_NN 59,400_CD 53,863_CD Other_JJ long-term_JJ debt_NN 11,828_CD 11,707_CD Non-equity_NN Deferred_VBN B_NNP Shares_NNP 11,310_CD 4,980_CD 36,569_CD 26,168_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Interest_NN rate_NN swaps_NNS 452_CD Euro_NNP currency_NN options_NNS 85_CD US$_$ currency_NN options_NNS 13_CD Forward_RB currency_NN contracts_NNS 146_CD 500_CD notes_NNS to_TO the_DT financial_JJ 76_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 25_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2001_CD Book_NNP values_NNS Fair_NNP values_VBZ Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS 000_CD 000_CD Fixed_VBN asset_NN investments_NNS 13,659_CD 13,903_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 4,534_CD 4,534_CD Short-term_JJ bank_NN deposits_NNS 22,358_CD 22,358_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long_JJ term_NN borrowings_NNS 7,257_CD 7,257_CD Long-term_JJ convertible_JJ debt_NN 59,400_CD 50,194_CD Other_JJ long-term_JJ debt_NN 12,288_CD 12,055_CD Non-equity_JJ Deferred_NNP A_NNP and_CC B_NNP Shares_NNP 22,620_CD 14,700_CD 61,014_CD 43,411_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Euro_NNP currency_NN options_NNS 38_CD US$_$ currency_NN options_NNS 20_CD 23_CD Forward_RB currency_NN contracts_NNS 46_CD 20_CD 31_CD f_SYM Currency_NNP exposures_NNS The_DT following_JJ analysis_NN shows_VBZ the_DT net_JJ monetary_JJ assets_NNS and_CC liabilities_NNS of_IN group_NN companies_NNS that_WDT are_VBP not_RB denominated_VBN in_IN their_PRP$ functional_JJ currency_NN and_CC therefore_RB give_VB rise_VB to_TO exchange_VB gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN in_IN both_DT 2002_CD and_CC 2001_CD ._.
31_CD December_NNP 2002_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Swiss_JJ $_$ Sterling_NNP $_$ US_PRP Euro_NNP francs_NNS Canadian_JJ Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000_CD 000_CD Sterling_NNP 2,232_CD 617_CD 1_CD 2,850_CD $_$ US_PRP 15,956_CD 9_CD 34_CD 15,999_CD Euro_NNP 2,025_CD 96_CD 2,225_CD 296_CD Swiss_JJ francs_NNS 928_CD 3,142_CD 528_CD 582_CD 1,104_CD $_$ Canadian_JJ 1,904_CD 400 130 550_CD 2,724_CD Swedish_NNP Krona_NNP 1,343_CD 1,343_CD 18,348_CD 5,870_CD 50_CD 2,775_CD 615_CD 10,368_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS 31_CD December_NNP 2001_CD French_JJ Swiss_JJ Sterling_NN $_$ US_PRP francs_NNS francs_NNS Other_JJ Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000_CD 000_CD Sterling_NNP 11,527_CD 49_CD 11,478_CD $_$ US_PRP 5,231_CD 5,231_CD French_JJ francs_NNS 2,260_CD 102_CD 25_CD 2,133_CD Swiss_JJ francs_NNS 3,568_CD 4,087_CD 406_CD 10_CD 8,071_CD $_$ Canadian_JJ 477_CD 477_CD 3,923_CD 16,193_CD 406_CD 25_CD 39_CD 12,662_CD 77_CD 25_CD Financial_NNP instruments_NNS continued_VBD g_JJ Hedging_NNP As_IN explained_VBN above_IN ,_, the_DT Groups_NNS policy_NN is_VBZ to_TO hedge_VB interest_NN rate_NN exposures_NNS through_IN the_DT use_NN of_IN interest_NN rate_NN swaps_NNS and_CC currency_NN exposures_NNS through_IN the_DT use_NN of_IN currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT extent_NN to_TO which_WDT the_DT Group_NNP has_VBZ off-balance_JJ sheet_NN unrecognised_JJ and_CC on-balance_JJ sheet_NN deferred_VBN gains_NNS and_CC losses_NNS in_IN respect_NN of_IN hedges_NNS at_IN the_DT beginning_NN and_CC end_NN of_IN the_DT year_NN :_: 31_CD December_NNP 2002_CD Unrecognised_NNP Deferred_NNP Gains_NNS Losses_NNS Net_JJ Total_JJ Gains_NNS Losses_NNS Net_JJ Total_JJ 000 000 000 000_CD 000_CD 000_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2002_CD 31_CD 31_CD 20_CD 20_CD Changes_NNS in_IN value_NN from_IN 1_CD January_NNP 2002_CD to_TO settlement_NN 262_CD 262_CD Gains_NNS losses_NNS arising_VBG in_IN 2001_CD recognized_VBN in_IN 2002 231 231_CD 20_CD 20_CD Gains_NNS losses_NNS not_RB recognized_VBN in_IN 2002_CD arising_VBG before_IN 1_CD January_NNP 2002_CD Arising_VBG in_IN 2002_CD 598_CD 98_CD 500_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2002_CD 598_CD 98_CD 500_CD At_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN had_VBD European_JJ style_NN accrual_NN forward_RB options_NNS to_TO purchase_VB 154,000_CD of_IN Swiss_JJ francs_NNS each_DT week_NN for_IN the_DT 26_CD weeks_NNS ending_VBG in_IN July_NNP 2002_CD and_CC 71,000_CD of_IN Euro_NNP each_DT week_NN for_IN the_DT 14_CD weeks_NNS ending_VBG in_IN April_NNP 2002_CD ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN had_VBD agreements_NNS in_IN place_NN for_IN American_JJ style_NN accrual_NN forward_RB options_NNS ,_, commencing_VBG in_IN January_NNP 2003_CD ,_, to_TO purchase_VB 113,000_CD of_IN US_NNP dollars_NNS for_IN the_DT 44_CD weeks_NNS ending_VBG in_IN November_NNP 2003_CD and_CC 44,000_CD of_IN Swedish_JJ Krona_NNP each_DT week_NN for_IN the_DT 45_CD weeks_NNS ending_VBG in_IN November_NNP 2003_CD ._.
Both_DT of_IN these_DT structures_NNS lapsed_VBD in_IN January_NNP and_CC February_NNP 2003_CD respectively_RB ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN had_VBD forward_JJ currency_NN contracts_NNS to_TO purchase_VB 4.5_CD million_CD of_IN Swiss_JJ francs_NNS ,_, 1.1_CD million_CD of_IN Euro_NNP and_CC 0.5_CD million_CD of_IN Swedish_NNP Krona_NNP ._.
The_DT excess_NN of_IN fair_JJ values_NNS over_IN book_NN values_NNS for_IN currency_NN options_NNS shown_VBN in_IN note_NN 25_CD e_SYM represents_VBZ the_DT unrecognised_JJ hedging_NN gain_NN on_IN these_DT instruments_NNS as_IN at_IN 31_CD December_NNP 2002_CD ._.
The_DT actual_JJ gains_NNS or_CC losses_NNS arising_VBG on_IN these_DT currency_NN options_NNS will_MD be_VB dependent_JJ on_IN future_JJ exchange_NN rates_NNS and_CC will_MD be_VB recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, in_IN 2003_CD ,_, as_IN the_DT operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
Unrecognised_JJ gains_NNS at_IN 31_CD December_NNP 2002_CD include_VBP 0.5_CD million_CD in_IN relation_NN to_TO the_DT cancellable_JJ swap_NN agreement_NN ._.
This_DT is_VBZ based_VBN upon_IN the_DT swap_NN agreement_NN continuing_VBG for_IN the_DT life_NN of_IN the_DT convertible_JJ bond_NN and_CC as_IN such_JJ the_DT gain_NN would_MD be_VB spread_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN until_IN 2005_CD ._.
The_DT Royal_NNP Bank_NNP of_IN Scotland_NNP exercised_VBD its_PRP$ right_NN to_TO cancel_VB the_DT swap_NN on_IN 19_CD December_NNP 2001_CD and_CC was_VBD replaced_VBN with_IN a_DT comparable_JJ swap_NN on_IN 27_CD February_NNP 2002_CD ._.
Similarly_RB ,_, it_PRP was_VBD again_RB canceled_VBN and_CC replaced_VBN on_IN 15_CD December_NNP 2002_CD ._.
31_CD December_NNP 2001_CD Unrecognised_NNP Deferred_NNP Gains_NNS Losses_NNS Net_JJ Total_JJ Gains_NNS Losses_NNS Net_JJ Total_JJ 000 000 000 000_CD 000_CD 000_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2001_CD 1,043_CD 104_CD 939_CD Changes_NNS in_IN value_NN from_IN 1_CD January_NNP 2001_CD to_TO settlement_NN 923 104 819_CD Gains_NNS losses_NNS arising_VBG in_IN 2000_CD recognized_VBN in_IN 2001 120 120_CD Gains_NNS losses_NNS not_RB recognized_VBN in_IN 2001_CD arising_VBG before_IN 1_CD January_NNP 2001_CD Arising_VBG in_IN 2001_CD 31_CD 31_CD 20_CD 20_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2001_CD 31_CD 31_CD 20_CD 20_CD notes_NNS to_TO the_DT financial_JJ 78_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 26_CD Pension_NN arrangements_NNS The_DT Group_NNP operates_VBZ various_JJ defined_VBN contribution_NN plans_NNS for_IN its_PRP$ employees_NNS in_IN the_DT UK_NNP ,_, Switzerland_NNP ,_, US_NNP ,_, Sweden_NNP and_CC Canada_NNP ._.
The_DT Groups_NNS contributions_NNS to_TO these_DT plans_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT period_NN to_TO which_WDT they_PRP relate_VBP ,_, and_CC the_DT assets_NNS are_VBP held_VBN in_IN separate_JJ trustee_NN administered_VBN funds_NNS ._.
The_DT Group_NNP operates_VBZ an_DT unfunded_JJ defined_VBN benefit_NN scheme_NN in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN France_NNP based_VBN on_IN the_DT national_JJ collective_JJ agreement_NN of_IN the_DT pharmaceutical_JJ industry_NN ,_, and_CC a_DT provision_NN of_IN 201,000_CD is_VBZ included_VBN in_IN Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS note_VBP 18_CD ._.
The_DT charge_NN for_IN the_DT year_NN was_VBD 128,000_CD ._.
Under_IN the_DT transitional_JJ provisions_NNS of_IN FRS17_NNP :_: Retirement_NNP Benefits_NNPS certain_JJ disclosures_NNS for_IN the_DT defined_VBN benefit_NN scheme_NN in_IN France_NNP are_VBP required_VBN as_IN follows_VBZ :_: As_IN at_IN December_NNP 2002_CD a_DT valuation_NN was_VBD performed_VBN by_IN professionally_RB qualified_VBN actuaries_NNS on_IN the_DT present_JJ value_NN of_IN the_DT accrued_VBN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN ._.
The_DT principal_JJ assumptions_NNS made_VBN by_IN the_DT actuaries_NNS were_VBD :_: 2002_CD 2001_CD %_NN per_IN annum_NN %_NN per_IN annum_NN Inflation_NN rate_NN 1.75_CD 2.0_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 2.75_CD 3.0_CD Discount_NNP rate_NN 5.25_CD 5.5_CD Analysis_NN of_IN amounts_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN respect_NN of_IN the_DT defined_VBN benefit_NN scheme_NN 2002_CD 000_CD Current_JJ service_NN cost_NN 24_CD Past_NNP service_NN cost_NN Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 21_CD Total_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN 45_CD Movement_NNP in_IN deficit_NN during_IN the_DT year_NN 2002_CD 000_CD At_IN 1_CD January_NNP 2002_CD 382_CD Exchange_NNP adjustment_NN 25_CD Total_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN 45_CD Benefit_NNP payments_NNS made_VBD 9_CD Actuarial_NNP gain_NN recognized_VBD in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 61_CD At_IN 31_CD December_NNP 2002_CD 382_CD 79_CD 26_CD Pension_NNP arrangements_NNS continued_VBD Amounts_NNS recorded_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS under_IN FRS17_NNP Experience_NN gains_NNS arising_VBG on_IN scheme_NN liabilities_NNS 000_CD 17_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 4_CD Changes_NNS in_IN assumption_NN relating_VBG to_TO the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 000_CD 44_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 12_CD Total_JJ actuarial_JJ gain_NN 000_CD 61_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 16_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS17_NNP 000_CD Profit_NN and_CC loss_NN reserve_NN per_IN balance_NN sheet_NN 264,006_CD Pension_NNP liability_NN under_IN FRS17_NNP 382_CD Pension_NNP liability_NN under_IN SSAP24_CD 201_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS17_NNP 264,187_CD Net_JJ assets_NNS under_IN FRS17_NNP 000_CD Net_JJ assets_NNS per_IN balance_NN sheet_NN 124,270_CD Pension_NNP liability_NN under_IN FRS17_NNP 382_CD Pension_NNP liability_NN under_IN SSAP24_NNP 201_CD Net_JJ assets_NNS under_IN FRS17_NNP 124,089_CD 27_CD Acquisitions_NNS a_DT Drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP On_IN 13_CD May_NNP 2002_CD SkyePharma_NNP acquired_VBD the_DT entire_JJ drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP ,_, of_IN Sweden_NNP ,_, for_IN 3.6_CD million_CD in_IN cash_NN including_VBG acquisition_NN costs_NNS and_CC the_DT assumption_NN of_IN 0.4_CD million_CD of_IN net_JJ liabilities_NNS ._.
The_DT acquired_VBN rights_NNS include_VBP Bioglans_NNP Biosphere_NNP injectable_JJ technology_NN and_CC those_DT rights_NNS to_TO DermaStick_NNP ,_, Crystalip_NNP and_CC ES-Gel_NNP topical_JJ drug_NN delivery_NN technologies_NNS that_WDT remained_VBD with_IN Bioglan_NNP after_IN the_DT January_NNP 2001_CD development_NN and_CC commercialisation_NN licensing_NN agreement_NN ._.
The_DT acquisition_NN method_NN has_VBZ been_VBN adopted_VBN and_CC goodwill_NN of_IN 4.0_CD million_CD arose_VBD on_IN the_DT acquisition_NN ._.
By_IN consideration_NN of_IN the_DT likely_JJ commercial_JJ life_NN of_IN the_DT technology_NN acquired_VBN ,_, the_DT Directors_NNS have_VBP determined_VBN that_IN a_DT suitable_JJ period_NN over_IN which_WDT to_TO amortise_VB the_DT goodwill_NN is_VBZ 20_CD years_NNS ._.
Book_NNP values_NNS and_CC fair_JJ values_NNS 000_CD Fixed_JJ assets_NNS Tangible_JJ assets_NNS 676_CD Current_JJ assets_NNS Debtors_NNS 44_CD Creditors_NNS amounts_VBZ falling_VBG due_JJ within_IN one_CD year_NN 1,095_CD Net_JJ current_JJ liabilities_NNS 1,051_CD Net_JJ liabilities_NNS 375_CD Satisfied_VBN by_IN :_: Cash_NN 3,500_CD Expenses_NNS relating_VBG to_TO the_DT transaction_NN 95_CD Consideration_NNP 3,595_CD Goodwill_NNP 3,970_CD notes_NNS to_TO the_DT financial_JJ 80_CD statements_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD 27_CD Acquisitions_NNS continued_VBD Results_NNS of_IN the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP The_NNP drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP prior_RB to_TO the_DT acquisition_NN formed_VBD part_NN of_IN Bioglan_NNP AB_NNP and_CC did_VBD not_RB report_VB as_IN a_DT separate_JJ unit_NN ._.
During_IN the_DT period_NN 13_CD May_NNP 2002_CD to_TO 31_CD December_NNP 2002_CD the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP contributed_VBD 0.5_CD million_CD to_TO turnover_NN ,_, a_DT loss_NN of_IN 1.5_CD million_CD to_TO operating_VBG profit_NN and_CC a_DT cash_NN outflow_NN of_IN 1.3_CD million_CD to_TO net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS ._.
b_NN RTP_NNP Pharma_NNP Inc._NNP ._.
SkyePharma_NNP achieved_VBD control_NN of_IN RTP_NNP Pharma_NNP Inc._NNP in_IN December_NNP 2001_CD when_WRB agreement_NN was_VBD reached_VBN to_TO acquire_VB the_DT majority_NN of_IN the_DT outstanding_JJ voting_NN shares_NNS in_IN RTP_NNP ._.
As_IN part_NN of_IN the_DT RTP_NNP acquisition_NN deferred_VBD consideration_NN may_MD be_VB due_JJ to_TO be_VB the_DT former_JJ RTP_NNP shareholders_NNS ._.
See_VB note_NN 23_CD b_NN :_: Shares_NNP and_CC warrants_NNS to_TO be_VB issued_VBN ._.
No_DT material_NN adjustments_NNS have_VBP been_VBN made_VBN to_TO the_DT provisional_JJ fair_JJ values_NNS ._.
28_CD Related_VBN party_NN transactions_NNS At_IN the_DT end_NN of_IN December_NNP 1998_CD ,_, Ian_NNP Gowrie-Smith_NNP through_IN a_DT family-owned_JJ trust_NN acquired_VBD a_DT 50_CD %_NN interest_NN in_IN 10_CD East_NNP 63rd_NNP Street_NNP Inc._NNP the_DT company_NN which_WDT owns_VBZ 10_CD East_NNP 63rd_NNP Street_NNP ,_, a_DT property_NN in_IN New_NNP York_NNP ._.
In_IN December_NNP 2002_CD Mr_NNP Gowrie-Smith_NNP acquired_VBD the_DT remaining_VBG 50_CD %_NN interest_NN ._.
SkyePharma_NNP PLC_NNP has_VBZ been_VBN in_IN occupation_NN of_IN that_DT property_NN since_IN January_NNP 1997_CD ,_, subject_JJ to_TO a_DT tenancy_NN agreement_NN renewed_VBN in_IN February_NNP 2001_CD at_IN which_WDT time_NN the_DT annual_JJ rent_NN was_VBD increased_VBN to_TO $_$ 360,000_CD per_IN annum_NN based_VBN upon_IN an_DT independent_JJ valuation_NN ._.
On_IN 1_CD April_NNP 2002_CD the_DT company_NN took_VBD additional_JJ space_NN within_IN the_DT property_NN at_IN which_WDT time_NN the_DT annual_JJ rent_NN was_VBD increased_VBN to_TO $_$ 420,000_CD per_IN annum_NN ._.
Until_IN 1_CD April_NNP 2002_CD approximately_RB one-third_NN of_IN the_DT premises_NNS was_VBD subleased_VBN to_TO Fifth_NNP Avenue_NNP Capital_NNP Inc._NNP an_DT unrelated_JJ company_NN ._.
29_CD Principal_NN subsidiary_NN undertakings_NNS Company_NN Country_NN of_IN incorporation_JJ %_NN Held_NNP Principal_NN activities_NNS 1_CD and_CC 2_CD SkyePharma_NNP Canada_NNP Holdings_NNP Inc._NNP ._.
Canada_NNP 100_CD Holding_NNP company_NN 2_CD SkyePharma_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD Research_NNP and_CC development_NN 1_CD SkyePharma_NNP Production_NNP SAS_NNP France_NNP 100_CD Manufacturing_NNP of_IN pharmaceuticals_NNS Krypton_NNP Limited_NNP Gibraltar_NNP 100_CD Exploitation_NNP of_IN intellectual_JJ property_NN 1_CD SkyePharma_NNP AB_NNP Sweden_NNP 100_CD Research_NNP and_CC development_NN Jago_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD Holding_NNP company_NN Jago_NNP Research_NNP AG_NNP Switzerland_NNP 100_CD Exploitation_NNP of_IN intellectual_JJ property_NN Jagotec_NNP AG_NNP Switzerland_NNP 100_CD Exploitation_NNP of_IN intellectual_JJ property_NN SkyePharma_NNP AG_NNP Switzerland_NNP 100_CD Research_NNP and_CC development_NN 1_CD SkyePharma_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD Holding_NNP company_NN 1_CD SkyePharma_NNP Holding_NNP Inc._NNP ._.
US_NNP 100_CD Holding_NNP company_NN SkyePharma_NNP Inc._NNP ._.
US_NNP 100_CD Development_NNP of_IN pharmaceuticals_NNS SkyePharma_NNP US_NNP Inc._NNP ._.
US_NNP 100_CD Development_NNP of_IN pharmaceuticals_NNS and_CC licensing_NN 1_CD Denotes_NNP investment_NN directly_RB held_VBN by_IN the_DT Company_NN ._.
2_CD On_IN 1_CD January_NNP 2003_CD SkyePharma_NNP Canada_NNP Holdings_NNP Inc._NNP and_CC SkyePharma_NNP Canada_NNP Inc._NNP were_VBD amalgamated_VBN under_IN Canadian_JJ Law_NN ._.
The_DT name_NN of_IN the_DT amalgamated_JJ corporation_NN is_VBZ SkyePharma_NNP Canada_NNP Inc._NNP ._.
Full_JJ details_NNS of_IN all_DT subsidiary_NN undertakings_NNS will_MD be_VB attached_VBN to_TO the_DT Companys_NNP Annual_JJ Return_NN to_TO be_VB filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
